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Abbreviations 
 
Abbreviation Full name 
3’-UTR   3’-untranslated region 
APS ammonium peroxodisulfate 
bHLH basic helix-loop-helix 
CSC cancer stem cell 
CDH1 cadherin 1 
cDNA complementary deoxyribonucleic acid 
ChIP chromatin immunoprecipitation 
CLL chronic lymphocytic leukemia 
CRC colorectal cancer  
DAPI 4',6-diamidino-2-phenylindole  
DLEU2 deleted in lymphocytic leukemia 2 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethyl sulfoxide 
dNTPs deoxynucleotide triphosphates 
DOX doxycycline 
DOXO doxorubicin 
EMT epithelial-mesenchymal transition 
FBS fetal bovine serum 
GFP/RFP green/red fluorescent protein 
H&E hematoxylin and eosin 
IF immunofluorescence 
MDM2 mouse double minute 2 homolog 
MET mesenchymal-epithelial transition 
miRNA microRNA 
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MYC myelocytomatosis oncogene 
NOD/SCID non-obese diabetic/severe combined  
 
Immunodeficient 
PCR polymerase chain reaction 
PI propidium iodide 
pre-miRNA precursor microRNA 
pri-miRNA primary microRNA 
qPCR quantitative polymerase chain reaction  
RIPA radio immunoprecipitation assay 
RISC RNA-induced silencing complex 
SD standard deviation 
SDS sodium dodecyl sulfate 
TEMED tetramethylethylenediamine 
TFAP4 transcriptional factor activating enhancer binding  
 
protein 4 
TGF-β   transforming growth factor-β 
VIM Vimentin 
ZEB1 zinc finger E-box binding homeobox 1 
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1 Introduction 
 
1.1 The biology of cancer 
 
Only a small number of the approximately 25,000 genes in the human 
genome has been linked to cancer. Alterations in the same gene are often 
associated with different forms of cancer. These genes can be divided into 
three main functional groups. 
  The first group, called proto-oncogenes, produces protein products that 
normally enhance cell division or inhibit normal cell death. Proto-oncogene 
proteins inhibit apoptosis and senescence of cancer cells. They also promote 
cancer progression by promoting migration/invasion, angiogenesis and 
metastasis. The mutated forms of these genes are called oncogenes (Figure 
1A) (Akinyeke et al., 2013; Cader et al., 2013). The second group, known as 
tumor suppressors, encodes proteins that normally prevent cancer cells 
division or cause cell death (Figure 1A) (Cader et al., 2013; Chen et al., 2013b). 
In tumor cells tumor suppressor genes loose their functions by mutation or 
inactivation by viral or epigenetic mechanisms. The third group of cancer 
causing genes is represented by DNA repair genes, which help prevent 
mutations that result in cancer (Park et al., 2013). 
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Figure 1 Oncogenes and tumor suppressors 
The main functions of oncogenes and tumor suppressors, which are deregulated 
during tumor progression. 
 
1.2 EMT and cancer 
 
“Epithelial-mesenchymal transition” (EMT), was first observed during the 
embryonic development (Savagner et al., 1994). Later it was shown that also 
cells in primary tumors undergo an EMT in order to invade and metastasize to 
distant organs (Thiery, 2002a). During EMT transformed epithelial cells can 
acquire the abilities for tumor invasion and metastasis, to resist apoptosis, and 
to disseminate (De Craene and Berx, 2013). Numerous laboratories 
demonstrated that EMT can be activated by a group of factors, SNAIL1, 
SNAIL2, Vimentin (VIM), ZEB1, ZEB2, ZNF281 and AP4, and repressed by 
CDH1 (Gregory et al., 2008; Hahn et al., 2013; Jackstadt et al., 2013; Siemens 
et al., 2011). Another important EMT regulator is transforming growth factor β 
(TGF-β). It up-regulates SNAIL1 and SNAIL2 and is an inducer of EMT in 
cancer cells (Siemens et al., 2011). As non-coding RNAs were reported to play 
Migration/Invasion 
Metastasis 
Oncogene 
Cell cycle/Proliferation 
Angiogenesis 
Senescence 
Apoptosis 
Tumor Suppressor 
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an important role in cancer metastasis, they are also potential hallmarks of the 
EMT program. For example, the miR-34/SNAIL1 and miR-200/ZEB1/2 
pathways. The members of the miR-34 family directly repress SNAIL1 and 
miR-200 members repress ZEB1/2, both promoting mesenchymal-epithelial 
transition (MET) (Gregory et al., 2008; Siemens et al., 2011). 
Cells undergoing an EMT also acquire other traits important for cancer cells. 
For example, they acquire features of cancer stem cells (CSCs). For example, 
elevated expression of β-catenin, a central component of Wnt and stem cell 
signaling, was found at the invasive front of the primary tumor in cells 
expressing EMT markers (Arend et al., 2013; Fodde and Brabletz, 2007). 
Stem-like cells in normal mammary glands and breast tumors also express 
EMT-related markers (Mani et al., 2008). 
 
     A B 
      
 
Figure 2 EMT processes and multiple crossroads 
(A) Role of EMT and MET in the progression of tumors. Normal epithelia give rise to 
adenomas which locally grow within the borders of a basement membrane. Additional 
transformation by epigenetic changes and genetic alterations leads to a carcinoma in 
situ, still surrounded by an intact basement membrane. Further changes can induce 
EMT which promotes local dissemination of carcinoma cells and invasion into and 
beyond the basement membrane. Thereby cells can intravasate into lymph or blood 
vessels, allowing their passive transport to distant organs (micrometastasis) or they 
can form a new carcinoma through MET (Thiery, 2002a). At secondary sites, solitary 
carcinoma cells can extravasate. Figure adapted to Thiery, 2002. (B) Involvement of 
EMT in multiple cellular processes (Thiery et al., 2009). Figure adapted to Thiery, 
2009. 
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1.3 The biology of colorectal cancer 
 
Colorectal cancer arises due to the accumulation of genetic and epigenetic 
changes, which transform normal glandular epithelial cells into invasive 
adenocarcinomas. In the past decades, intensive research identified two major 
different molecular mechanisms as the cause of colorectal cancer: 
chromosomal instability (CIN) and microsatellite instability (MSI) (Al-Sohaily et 
al., 2012; Fearon and Vogelstein, 1990). CRC with CIN represent 80% of 
sporadic CRC and is characterized by allelic losses on the short arm of 
chromosome 17 and 8 and on the long arm of chromosome 5, 18 and 22. 
These allelic losses are linked to mutations in TP53, APC, SMAD2 and 
SMAD4 genes (Rustgi, 2013). It is still controversial how the CIN phenotype is 
generated. Hadjihannas et al claimed that aberrant Wnt/beta-catenin signaling 
results in CIN (He et al., 2007). Activated Wnt/beta-catenin signaling induces 
the transcription of target genes, including conductin/AXIN2, which also binds 
to polo-like kinase 1. This may compromise the spindle checkpoint, which 
suppresses chromosomal instability (Hadjihannas et al., 2006). On the other 
hand, MSI, which results from a mismatch repair (MMR) deficiency is present 
in 12-15% of CRC cases. MMR deficiency leads to the accumulation of 
mutations in genes, such as TGFBRII, BAX or CASPASE5, which regulate the 
cell cycle and apoptosis (Fleming et al., 2013; Lee et al., 2013). CRC shows 
genetic heterogeneity as shown above, but the consequences of signaling 
pathway alterations are similar. For example, the RAS-MAP kinase pathway is 
triggered by KRAS mutations in CIN tumors or by BRAF mutations in MSI 
tumors. The p53 pathway is inactivated by TP53 inactivation due to mutations 
and deletions in CIN and MSI tumors or, alternatively, by BAX inactivating 
mutations in MSI tumors (Friedman et al., 2009; Laurent-Puig et al., 2010). 
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1.4 p53 
 
p53 is presumably the best studied tumor suppressor. Inactivation of p53 is 
observed in 50% of all human cancers (Hollstein et al., 1991). p53 and its 
numerous target genes play an essential role in suppressing many human 
tumors (Levine et al., 2004; Vousden and Prives, 2009). 
 
1.4.1 p53 enters the microRNA world 
 
miRNAs play a role in the regulation of proliferation, differentiation and 
apoptosis, and are intimately connected to the p53 network (Hermeking, 2012, 
Nature Reviews Cancer). Several groups documented that p53 induces the 
expression of several miRNAs and promotes the maturation of specific 
miRNAs, which mediate tumor suppression by p53 (Kim et al., 2011b; 
Shimono et al., 2009; Xu et al., 2009). Some laboratories reported that p53 
inhibits cell proliferation and tumor angiogenesis through miR-107 (Chen et al., 
2013a; Corney et al., 2007). The miR-34 family includes the miR-34a and 
miR-34b/c genes, which were the first miRNAs found to be directly regulated 
by p53. Activation of p53 induces miR-34, which represses the EMT-induced 
transcription factor SNAIL (Siemens et al., 2011). Similarly, the p53-induced 
miR-200 family represses the EMT-TFs ZEB1/ZEB2, thereby forming a 
double-negative feed-back loop (Chang et al., 2011).  
 
1.5 microRNAs and cancer 
 
As the name implies, microRNAs (miRNAs) are short, single-stranded RNAs 
of ~22 nucleotides length. They constitute a relatively new class of gene 
regulators in plants and animals (Bartel, 2004). The earliest description of 
miRNAs can be found in Caenorhabditis elegans, where they function as 
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regulators of developmental timing (Lee et al., 1993; Wightman et al., 1993). 
To date, approximately 2500 miRNAs have been identified in humans. miRNAs 
are known to modulate the stability of the mRNA targets through 
3’-untranslated regions (3’-UTR). Over 60% of all mammalian mRNAs are 
predicted to be targets of miRNAs (Friedman et al., 2009). miRNAs are 
involved in many processes, such as development, stem cell division, 
apoptosis, disease and cancer (Cheng et al., 2005a; Cheng et al., 2005b; 
Cimmino et al., 2005). 
 
1.5.1 The biogenesis of miRNAs 
 
miRNAs are generated by a unique biogenesis, which is closely related to 
their regulatory functions (Bartel, 2004). As shown in Figure 3, they are 
encoded by specific host genes in genomic DNA, which are transcribed by 
RNA polymerase II to yield the primary transcript (pri-miRNA) containing a 
stem-loop structure of ~500 to 3,000 bp. pri-miRNAs are capped and 
polyadenylated and possess hairpin structures that comprise the future mature 
sequence in the stem. These pri-miRNAs in the nucleus are further 
transformed into ~60-70 nt hairpin-shaped precursor miRNAs (pre-miRNAs) by 
the Drosha enzyme, a type III RNase, in a complex with its co-factor DGR8 
(DiGeorge syndrome critical region 8 homolog) (Han et al., 2006). The 
pre-miRNAs are exported into the cytoplasm by the RAN GTP-dependent 
transporter Exportin-5 (Exp-5) (Lund et al., 2004). After being transported into 
the cytoplasm, the pre-miRNA hairpin is cleaved by Dicer (RNase III) and with 
assistance of TRBP (TAR RNA-binding protein, also known as TARBP2) a ~22 
nt RNA duplex is generated (Chendrimada et al., 2005). One of the two strands, 
the so-called passenger strand (miRNA*), is released and degraded. Another 
strand which is termed guide strand or miRNA, is loaded into the 
Argonaute-containing RNA-induced silencing complex (RISC). miRNA-RISC 
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complexes are able to silence the target mRNAs via imperfect 
complementarity with target sequences located most commonly in the 3’-UTR. 
(Esquela-Kerscher and Slack, 2006; Lujambio and Lowe, 2012; Ruegger and 
Grosshans, 2012). 
 
 
 
Figure 3 The biogenesis of microRNAs  
MicroRNAs (miRNAs) are mainly transcribed by RNA Polymerase II (Pol II) in the 
nucleus to synthesize a primary transcript called pri-miRNA. Then, the pri-miRNA 
transcript is processed by the RNase III enzyme Drosha to release a~70-nucleotide 
pre-miRNA precursor product named pre-miRNA. RAN-GTP and exportin 5 transport 
the pre-miRNA into the cytoplasm. Subsequently, another RNase III enzyme, Dicer, 
processes the pre-miRNA to generate a transient 22-nucleotide miRNA in 
conjunction with TRBP. One of the two strands, named miRNA, is then loaded into the 
miRNA-associated RNA-induced silencing complex (miR-RISC), which includes the 
Argonaute protein, and mature single-stranded miRNA. Then, mature miRNA binds to 
complementary sites in the 3'-UTRs of target mRNA genes and regulates gene 
expression (Esquela-Kerscher and Slack, 2006). Figure adapted to Esquela-Kerscher 
and Slack, 2006. 
 
1.5.2 miRNAs and diseases 
 
Recently, microRNAs have attracted a lot of attention because of their 
functions in human diseases. miRNAs have been identified as important 
regulators in a variety of biological processes including embryogenesis, 
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differentiation, proliferation, apoptosis, signal transduction and carcinogenesis. 
Abnormal expression of miRNAs is involved in the pathogenesis of human 
diseases including cancer, hematopoietic diseases and viral infection.  
 
1.5.3 miRNAs and cancer 
 
The first genetic proof of a role of miRNAs in human cancers was obtained 
in 2002. Croce and colleagues observed that a small genomic region located 
on chromosome 13q14 is commonly deleted in chronic lymphocytic leukemia 
(CLL). Since the region contains the DLEU2 gene which encodes 
miR-15a/16-1 this finding suggests a link between these miRNAs and CLL 
(Calin et al., 2002). Moreover, 52.8% (98 of 186) of annotated human miRNAs 
locate in the fragile sites, which are linked to cancer (Calin et al., 2004). This 
indicates that miRNAs may have a crucial function in cancer progression. For 
example, miR-125b maps to the fragile site of chromosome 11q24, which is 
deleted in a subset of breast, lung, ovarian and cervical cancers (Feliciano et 
al., 2013; Gong et al., 2013). That suggested that miR-125b functions as a 
tumor suppressor in these cancer types. On the other hand, certain miRNAs 
exhibit oncogenic properties. For instance, miR-21 was found to stimulate cell 
invasion and metastasis in different tumor types such as breast cancer, colon 
cancer and glioma (Asangani et al., 2008; Gabriely et al., 2008; Zhu et al., 
2008). Several examples of miRNAs that are aberrantly expressed in cancer 
and function either a tumor suppressor or as oncogenes are summarized in 
Table I. 
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Table I The functions of miRNAs as oncogenes or tumor suppressors in cancer.  
miRNA Genomic location Cancer type Targets Mechanism 
Oncogenes 
miR-21 17q23.1 colon, breast, lung, liver, stomach PTEN, TPM1 anti-apoptotic factor, EMT, 
  cancer  cancer stem cell phenotype 
miR-155 21q21.3 lung and breast cancer, AML, c-maf, SHIP1 Wnt signaling, tumor metastasis, 
  Hodgkin lymphoma  cell proliferation, NF-kB 
miR-17~92 13q22 breast, lung and colon cancer E2F1, Bim, PTEN apoptosis, stemness 
  neuroblastoma, CLL STAT5, Nanog  
miR-373 19q13 testicular, breast, liver, prostate CD44, TNFAIP1 invasion/metastasis, stemness, 
  cancer RAD23B TGF-β signaling, hypoxia-inducible 
miR-10b 2q31 breast, ovarian, gastric, bladder, HOXD10, TBX5 TGF-β signaling, EMT, cell motility, 
  malignant glioma Tiam1, MAPRE1 cell proliferation, hypoxia-inducible 
miR-221/222 Xp11.3 lung, hepatocellular carcinoma, PTEN, HECTD2, cell proliferation/apoptosis, 
  Invasive ductal carcinoma KIT, RAB1A JAK/STAT signaling 
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Tumor suppressors 
miR-15a/16-1 13q14 CCL, BCL, colon and breast cancer BCL2, CCND1, frequently deleted, apoptosis, 
   VEGF, AP4,WT-1 decreases tumorigenicity, EMT 
miR-143/145 5q32 colon, breast, prostate, lung, Osx, KLF4 Toll-like receptor signaling, stemness, 
  lymphoid cancer GOLM1 cell proliferation, migration/invasion 
let-7 family  lung, breast and ovarian cancer RAS, c-MYC, apoptosis, Wnt signaling, 
   ITGB3, HMGA2 cell proliferation, Lin28-Let-7 axis 
miR-29 7q32 and 1q30 CLL, AML, lung and breast cancer TCL-1, MCL1, apoptosis, decreases tumorigenicity 
   DNMT3a TGF-β signaling 
miR-34 Family 1p36 and11q23 breast, kidney, colon and lung SNAIL1, c-MYC, induces apoptosis, EMT, apoptosis, 
  cancer ZNF281 decreases tumorigenicity, stemness 
miR-200 Family 1p36 colon, breast and prostate cancer ZEB1/2, CCNE2, EMT, stemness, cell cycle, 
   FLT1, VEGF angiogenesis 
miR-101 1p31.3 prostate, breast, ovarian, lung and EZH2, NLK, cell proliferation, EMT 
  colon cancer ZEB1/2, c-MET  
miR-26a 3p22 liver, ovarian cancer CCND2, CCNE2 cell proliferation and motility, 
   HMGA1, LIN28B NF-kB signaling 
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Abbreviations: BCL2, B-cell CLL/lymphoma 2; Bim, BCL-2-interacting mediator of cell 
death; CLL, chronic lymphocytic leukemia; CCND2, cyclin D2; CCNE2, cyclin E2; 
c-MET, c-MET proto-oncogene; DNMT3a, DNA (cytosine-5-)-methyltransferase 3 
alpha; ECM, extracellular matrix; EZH2, enhancer of zeste 2 polycomb repressive 
complex 2 subunit; EMT, epithelial-mesenchymal transition; E2F1, E2F transcription 
factor 1; FLT1, fms-related tyrosine kinase 1; GOLM1, golgi membrane protein 1; 
HOXD10, homeobox D10; HMGA1/2, high mobility group AT-hook 1/2; ITGB3, 
integrin, beta 3; LIN28B, lin-28 homolog B; maf, v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog; MCL1, myeloid cell leukemia sequence 1; MYC, 
v-myc avian myelocytomatosis viral oncogene homolog; NF-kB, nuclear factor-kB; 
Osx, Osterix; NLK, Nemo-like kinase; PTEN, phosphatase and tensin homolog; 
SHIP1, Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1; SNAIL1, snail 
family zinc finger 1; TCL-1, T-cell leukemia/lymphoma 1; TPM1, tropomyosin 1; VEGF, 
vascular endothelial growth factor; ZEB1/2, zinc finger E-box binding homeobox 1/2; 
ZNF281, zinc finger protein 281. 
 
1.6 The miR-15a/16-1 family 
 
The deregulation of many miRNAs observed in cancer suggests that they 
may be causally involved in the initiation or progression of cancer. Calin et al 
showed that miR-15a/16-1 is involved in CLL, the most common form of adult 
leukemia in the Western world (Calin et al., 2002). Chiorazziet al. found that 
DLEU2, the host gene of miR-15a and miR-16-1, is deleted in half of CLL 
cases (Chiorazzi et al., 2005). This suggested that the two miRNAs could be 
the tumor suppressor genes. 
Several studies have shown that miR-15a and miR-16-1 are deleted or 
down-regulated in tumor cells, suggesting that these two miRNA genes could 
be the “hot spots” in cancer transformation (Bonci et al., 2008; Calin and Croce, 
2006). Moreover, Cimmino et al found that miR-15a/16-1 induces apoptosis by 
targeting the oncogene BCL2. They noted that the expression of miR-15a and 
miR-16-1 inversely correlates with BCL2 expression in CLL and miR-15a/16-1 
represses BCL2 at the post-transcriptional level (Cimmino et al., 2005). 
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Figure 4 DLEU2 is the host gene of miR-15a and miR-16-1 
Schematic figures present the human 13q14 and mouse 14qC3. Thick arrows show 
the 5’-3’ orientation. MDR, minimal deleted region (Klein et al., 2010). Figure adapted 
to Klein et al., 2010. 
 
1.7 The transcription factor AP4 
 
The AP4/TFAP4 (Transcription factor AP4) protein activates both viral and 
cellular genes by binding to the symmetrical DNA sequence, CAGCTG. The 
AP4 is a basic helix-loop-helix (bHLH) protein (Hu et al., 1990). It was 
identified first as a cellular protein that binds to the SV40 enhancer and 
interacts synergistically with AP-1 to activate viral late gene transcription 
(Mermod et al., 1988). Unlike other bHLH transcription factors, AP4 contains 
two additional protein dimerization motifs, which consist of the leucine zipper 
elements LZ1 and LZ2 (Jung and Hermeking, 2009). 
AP4 was shown to play an important role in modulation of cellular functions, 
such as viral production (Imai and Okamoto, 2006), cell growth and survival 
(Tsujimoto et al., 2005), immune response (Aranburu et al., 2001; Bae et al., 
2001), and angiogenesis (Cui et al., 1998) by regulation of specific target 
genes. 
Introduction 
15 
 
Recently, the AP4 gene was characterized as a c-MYC target gene and its 
product was shown to repress p21 in order to maintain cells in a proliferative, 
progenitor-like state (Jung and Hermeking, 2009; Jung et al., 2008). 
Furthermore, Jackstadt et al revealed that ectopic expression of AP4 induces 
EMT by regulating a specific set of genes, such as SNAIL, VIM, and repressing 
CDH1 expression in colorectal cancer (CRC) cells (Jackstadt et al., 2013). In 
accordance with these results, AP4 also enhances migration/invasion, 
whereas knock-down of AP4 decreases the formation of lung metastasis by 
CRC cell in mice (Jackstadt et al., 2013). 
 
1.8 The transcription factor MYC 
 
The MYC family comprises the transcription factors c-MYC, n-MYC, L-MYC, 
b-MYC and S-MYC, and performs essential functions during proliferation, 
growth, survival and differentiation of normal cells. MYC transcription factors 
belong to the class of basic region/helix-loop-helix/leucine zipper (bHLHZip) 
transcription factors and heterodimerize with Max, another bHLHZip protein. 
The MYC/MAX heterodimers binds to the 6-nucleotide DNA consensus 
sequence CACGTC, the so-called E-box (Luscher and Larsson, 1999). 
The v-MYC oncogene was discovered in a retrovirus that causes 
myelocytomatosis (Duesberg and Vogt, 1979; Hu et al., 1979). The expression 
of n-MYC and L-MYC genes is largely confined to particular stages of the 
embryonic development and to immature cells of the hematopoietic and 
neuronal compartment of adults. In contrast, the c-MYC gene is expressed in 
dividing cells and is down-regulated during differentiation when cells stop to 
proliferate (Meyer and Penn, 2008). c-MYC expression is induced by multiple 
mitogenic signaling pathways including Wnt, Notch and STAT signaling, as 
well as by activation receptor tyrosine kinases (RTKs), such as PDGFR 
(platelet-derived growth factor receptor), EGFR (epidermal growth factor 
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receptor) and IGFR (insulin-like growth factor 1 receptor) (Bommer et al., 2007; 
Chang et al., 2007; Raver-Shapira et al., 2007). 
As has been mentioned, MYC is crucial in normal cell proliferation and 
growth. However, deregulation of MYC gene can result in an enlarged pool of 
proliferating and self-renewing cells, which are more likely to acquire further 
mutations that accelerate tumorigenesis. Indeed, activation of the MYC 
oncogene, as a consequence of translocation, amplification, point mutations or 
defects in upstream regulators, contributes to the development of a wide 
variety of human cancers including leukemia, lymphoma and solid cancers, 
such as breast cancer and neuroblastoma (Aulmann et al., 2006; Bourhis et al., 
1990). However, deregulation of MYC also triggers intrinsic tumor suppressor 
mechanisms including apoptosis, cellular senescence and DNA damage 
responses. These checkpoint responses constitute main barriers for tumor 
development (Liu et al., 2012). The seemingly antagonistic functions of MYC 
functions have been comprehensively reviewed recently (Larsson and 
Henriksson, 2010). 
 
1.9 Aims of the Study 
 
AP4 functions as an oncogene that regulates EMT and thereby mediates 
invasion and migration. The goal of this study was to identify miRNAs, which 
regulate AP4 and may thereby exert tumor suppressive functions. 
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2 Materials 
2.1 Human cancer cell lines 
Five colon cancer cell lines, one kidney cancer cell line and one lung cancer 
cell line which stored by our group were used in this study. The SW480 cell line 
was established from a 50 years old male patient of Dukes’ type B, colorectal 
adenocarcinoma. The SW620 cell line was established from a 51 years old 
male patient of Dukes’ type C, colorectal adenocarcinoma. The DLD1 cell line 
was established from a male patient of Dukes’ type C, colorectal 
adenocarcinoma. The HCT116 cell line was established from a male patient of 
colorectal carcinoma. The RKO cell line was established from a patient of 
colorectal carcinoma. The kidney cell line HEK-293 was established from a 
fetus of the embryonic kidney. The lung cancer cell line H1299 was 
established from a 43 years old male patient of non-small cell lung cancer. 
  
2.2 Chemicals 
2.2.1 General chemicals 
 
Name Company 
Ampicillin Sigma-Aldrich, St. Louis, MD, USA 
Christal violet Carl Roth GmbH, Karlsruhe, Germany 
DMEM (1×) GlutaMAX TM–I Life Technologies Corporation, Grand  
 Island, NY, USA 
DMSO  Carl Roth GmbH, Karlsruhe, Germany 
Doxorubicin Sigma-Aldrich, St. Louis, MD, USA 
Doxycycline hyclate Sigma-Aldrich, St. Louis, MD, USA 
Ethanol Carl Roth GmbH, Karlsruhe, Germany 
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Ethidium bromide Carl Roth GmbH, Karlsruhe, Germany 
FBS (fetal bovine serum)  Gibco®, Life Technologies Corporation,  
 Grand Island, NY, USA 
HBSS+/+, HBSS -/- Life Technologies Corporation, Grand  
 Island, NY, USA 
Hygromycin B Invitrogen GmbH, Karlsruhe, Germany 
McCoy’s 5A medium (1x) Life Technologies Corporation, Grand  
 Island, NY, USA 
Methanol Carl Roth GmbH, Karlsruhe, Germany 
Penicillin/Streptomycin 100 ml Life Technologies Corporation, Grand  
 Island, NY, USA 
Puromycin dihydrochloride Sigma-Aldrich, St. Louis, MD, USA 
Trypsin (10x, phenol-red free) Invitrogen GmbH, Karlsruhe, Germany 
Tween® 20 Sigma-Aldrich, St. Louis, MD, USA 
Distilled Water               Life Technologies GmbH, Darmstadt,  
 Germany 
 
2.2.2 Cell culture materials 
 
Name Company 
25 cm2, 75 cm2 , 150 cm2, culture flask, 
 
Corning Incorporated Corning, NY,  
Canted Neck USA 
6-, 12-, 24-, and 96-well cell culture
 
Corning Incorporated Corning, NY,  
Cluster USA 
Costar® STRIPETTE®
 
Corning Incorporated Corning, NY,  
2 ml, 5 ml, 25 ml, 50 ml USA 
Cell Culture Dish 60 mm×15 mm
 
Corning Incorporated Corning, NY,  
and 100 mm×20 mm style USA 
Materials 
19 
 
 
2.2.3 Cell culture medium 
 
Cell line Medium 
SW480/SW620/H1299  90% DMEM medium     
cell lines medium         10% FBS 
 1% Penicillin/Streptomycin 
HCT 116/RKO/DLD1  90% McCoy’s medium 
cell lines medium            10% FBS 
 1% Penicillin/Streptomycin 
 
2.2.4 Cell storage medium 
 
Component Percentage 
DMEM/McCoy’s medium 40% 
FBS 50% 
DMSO 10% 
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2.2.5 Vectors 
 
Name Insert Reference 
pRTR  (Jackstadt et al., 2013) 
pRTR-p53-VSV human p53 (Siemens et al., 2011) 
pRTR-AP4-VSV human AP4 (Jackstadt et al., 2013) 
pRTS-miR-15a/16-1 human miR-15a/16-1 (Klein et al., 2010) 
TW empty  (Bonci et al., 2008) 
TW-miR-15a/16-1 human miR-15a/-16-1 (Bonci et al., 2008) 
TW-miR-15a/16-1 sponge human miR-15a/-16-1 (Bonci et al., 2008) 
pGL3-control-MCS   
pGL3-AP4 3’-UTR human AP4 3’-UTR (Shi et al., 2014) 
pGL3-AP4 3’-UTR MUT human AP4 3’-UTR MUT (Shi et al., 2014) 
pRL Renilla  
 
2.2.6 Materials for transfection and real time PCR 
 
Name Company 
Fast SYBR® Green Master Mix Applied Biosystems, Foster City, CA, 
USA       FuGene® 6 Transfection  Promega, Madison, WI, USA 
reagent    
HiPerFect Transfection reagent Qiagen GmbH, Hilden, Germany 
Lipofectamine® 2000 Invitrogen GmbH, Van Allen Way 
Carlsbad,   A, USA 
Opti-MEM®                    Life Technologies Corporation, Grand 
Island,  NY, USA 
DNase I (RNase-free)              Sigma-Aldrich, St. Louis, MD, USA 
High Pure miRNA Isolation Kit       Roche Diagnostics GmbH, Mannheim,  
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 Germany 
High Pure RNA Isolation Kit Roche Diagnostics GmbH, Mannheim, 
 Germany 
Verso cDNA Kit                 Thermo Fisher Scientific Inc., Waltham, 
MA,   USA 
miRCURY LNA™ Universal RT 
microRNA PCR, Universal cDNA 
Synthesis Kit II, 8-64 xns 
Exiqon A/S, Vedbaek, Denmark 
miRCURY LNA™ Universal RT 
microRNA PCR, SYBR® Green master 
mix, universal RT, 2.5 ml 
Exiqon A/S, Vedbaek, Denmark 
 
 
  
2.2.7 Materials for Western blot, flow cytometry and immunofluorescence 
 
Name Company                   
0.22 μm filter (Millex®-GV) Merck Millipore Ltd. Tullgreen,  
 Carrigwohill, Co. Cork, IRL 
APS  Carl Roth GmbH, Karlsruhe, Germany 
β-mecaptoethanol Sigma-Aldrich Chemie GmbH,  
 Steinheim, Germany 
Complete mini protease inhibitor  Roche Diagnostics GmbH, Mannheim, 
cocktail    Germany 
DAPI  Carl Roth GmbH, Karlsruhe, Germany 
ImmobilonTM Western Millipore Corporation, Billerica,  
 MA, USA 
Immobilon-P Transfer Membrane Immobilon, Merck Millipore, Billerica,  
 MA, USA 
Micro BCA Protein Assay Kit      Pierce, Thermo Fisher Scientific, Inc.,  
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 Rockford, IL, USA 
NaCl Carl Roth GmbH, Karlsruhe, Germany 
Nonidet® P40 Substitute Sigma-Aldrich, St. Louis, MD, USA 
PageRuler™ Thermo Fisher Scientific, Inc.,  
Prestained Protein Ladder Rockford, IL, USA 
Paraformaldehyde Merck KGaA, Darmstadt, Germany 
ProLong Gold Antifade Invitrogen GmbH, Karlsruhe, Germany 
Propidium iodide Sigma-Aldrich, St. Louis, MD, USA 
RNase A Sigma-Aldrich, St. Louis, MD, USA 
Rotiphorese Gel 30 (37, 5:1) Carl Roth GmbH, Karlsruhe,  
 Germany 
SDS (sodium dodecyl sulfate)       Carl Roth GmbH, Karlsruhe, Germany 
Skim Milk Powder Fluka, Sigma-Aldrich, St. Louis, MD,  
 USA 
Tris-base Carl Roth GmbH, Karlsruhe, Germany 
Triton X 100 Carl Roth GmbH, Karlsruhe, Germany 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
Western LightingTM Plus-ECL Millipore Corporation, Billerica, 
 MA, USA 
 
RIPA buffer (for protein lysates, 100 ml): 
 1% NP40 
 0.5% sodium deoxycholate 
 0.1% SDS 
 NaCl 150 mM 
 50 mM TrisHCl (pH 8.0)  
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2xLaemmli buffer (9 ml): 
 1 ml, 125 mM TrisHCl (pH 6.8) 
 4 ml, 10% SDS 
 2 ml, 20% glycerol 
 1 ml, 0.5% bromophenol blue (in H2O)  
 1 ml ddH2O 
 10% β-mercaptoethanol, added immediately before use 
 
10xTris-glycine-SDS running buffer (5 L, for protein gels): 
 720 g glycine  
 150 g Tris base  
 50 g SDS  
 pH 8.3-8.7 
 add ddH2O to 5 liters  
 
Towbin buffer (for protein blotting, 1 L, 10×): 
 30.28 g glycine 
 144.14 g Tris-base 
 ddH2O (pH 8.6) 
 
Towbin buffer (for protein blotting, 1×): 
 10%, 10×Towbin Buffer 
 20% methanol 
 70% ddH2O 
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10xTBST (5 L): 
 500 ml 1M Tris (pH 8.0) 
 438.3 g NaCl  
 50 ml Tween 20 
 add ddH2O to 5 liters 
 
Resolving gel, 10%, 10 ml: 
 H2O 4.12 ml 
 4xLower Tris 2.5 ml 
 30% PAA37.5/1      3.33 ml 
 10% APS 0.075 ml 
 TEMED 0.0075 ml 
 
Stacking gel, 4 ml: 
 H2O 2.45 ml 
 4x Upper Tris 1 ml 
 30% PAA37.5/1      0.67 ml 
 10% APS 0.005 ml 
 TEMED 0.0075 ml 
 
Propidium iodide staining solution (PI): 
 800 µl propidiumiodide (1.5 mg/ml) 
 1000 µl RNase A (10 mg/ml) 
 20 ml PBS 0.1% Triton X 100 
Storage at 4°C in dark. 
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Staining solution (20 ml): 
 PBS 18.1 ml 
 Triton X 100 100 µl 
 RNase 1000 µl 
 PI 800 µl 
The solution was passed through a 0.22 µm filter before use. 
 
2.2.8 Materials for migration, invasion and would healing 
 
Name Company                       
BD Matrigel™    BD Bioscience, Heidelberg,  
 Germany 
Boyden chamber transwell Corning Inc., Corning, NY, USA 
IBIDI chamber IBIDI GmbH, Munich, Germany 
Mitomycin C Sigma-Aldrich, St. Louis, MD, USA 
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2.2.9 Materials for cloning and dual-reporter luciferase assays 
 
Name Company 
dNTPs Thermo Fisher Scientific Inc., Waltham,  
 MA, USA 
Gene Ruler 100 bp plus DNA        Fermentas GmbH, St. Leon-Rot, Germany 
ladder  
Hi-Di™ Formamide Applied Biosystems, Foster City, CA, USA 
FIREPol® DNA polymerase Solis BioDyne, Tartu, Estonia 
Platinum® Taq DNA polymerase Invitrogen GmbH, Karlsruhe, Germany 
Restriction endonucleases 
 
New England Biolabs GmbH, Frankfurt, 
Germany 
T4 DNA ligase Thermo Fisher Scientific Inc., Waltham, 
MA, USA 
DyeEx® 2.0 Spin Kit Qiagen GmbH, Hilden, Germany 
Pure Yield™ Plasmid Midiprep 
System 
Promega GmbH, Mannheim, Germany 
 QIAprep Spin Miniprep Kit   Qiagen GmbH, Hilden, Germany 
QIAquick Gel Extraction Kit   Qiagen GmbH, Hilden, Germany 
QuikChange II 
XL Site-Directed Mutagenesis Kit 
Stratagene, Agilent Technologies GmbH & 
Co. KG, Waldbronn, Germany 
Dual-Luciferase® Reporter Assay 
System  
Promega Corporation, WI, USA 
 
 
Mini Prep buffer 1 (MP1): 
 
 50 mM Tris-HCl (pH 8) 
 10 mM EDTA 
 100 µg/ml RNase A 
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Mini Prep buffer 2 (MP2): 
 
 200 mM NaOH 
 1% SDS 
 
Mini Prep buffer 3 (MP3): 
 
 3 M potassium acetate 
 pH 5.5 
    
2.2.10 Oligonucleotides used for cloning and site-directed mutagenesis 
 
Name Sequence(5’ - 3’) 
AP4 3’-UTR WT Fwd 5’-ACTCCGAGGCCTCAGACAGTGAC-3’ 
AP4 3’-UTR WT Rev 5’-TGGAAGATGAGACCTGGAGGCAGAG-3’ 
AP4 3’-UTR Mutant 
Fwd 
5’-TGCTTCTTGGTTGGGGTTTCCAGTAGCTG
TGCCCCCCTCCCCCTT-3’ 
AP4 3’-UTR Mutant 
Rev 
5’-AAGGGGGAGGGGGGCACAGCTACTGGAA
ACCCCAACCAAGAAGCA-3’ 
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2.2.11 Oligonucleotides used for qPCR analyses  
 
Name Sequence(5’ - 3’) 
pri-miR-15a/16-1 Fwd 5’-GCAATTACAGTATTTTAAGAGATGAT-3’  
pri-miR-15a/16-1 Rev  5’-CATACTCTACAGTTGTGTTTTAATGT-3’  
AP4 Fwd 5’-GCAGGCAATCCAGCACAT-3’  
AP4 Rev 5’-GGAGGCGGTGTCAGAGGT-3’  
β-actin Fwd 5’-TGACATTAAGGAGAAGCTGTGCTAC-3’  
β-actin Rev  5’-GAGTTGAAGGTAGTTTCGTGGATG-3’  
SNAIL Fwd 5’-GCACATCCGAAGCCACAC-3’  
SNAIL Rev  5’-GGAGAAGGTCCGAGCACA-3’  
CDH1 Fwd 5’-CCCGGGACAACGTTTATTAC-3’  
CDH1 Rev 5’-GCTGGCTCAAGTCAAAGTCC-3’  
Vimentin Fwd 5’-TACAGGAAGCTGCTGGAAGG-3’  
Vimentin Rev  5’-ACCAGAGGGAGTGAATCCAG-3’  
ZEB1 Fwd 5’-TCAAAAGGAAGTCAATGGACAA-3’  
ZEB1 Rev  5’-GTGCAGGAGGGACCTCTTTA-3’  
 
2.2.12 Oligonucleotides used for qChIP analyses 
 
Name Sequence(5’- 3’) 
DLEU EX 1A Fwd 5’-CATGCGTAAAAATGTCGGGAA-3’ 
DLEU EX 1A Rev 5’-GGTTATTCCTGTCCGCTAGATTGA-3’ 
DLEU EX 1B Fwd 5’-GCGCGCTGTGTACTTAGG-3’ 
DLEU EX 1B Rev 5’-CAACATTGCGAAAAGGAG-3’ 
AchR Fwd 5’-CCTTCATTGGGATCACCACG-3’ 
AchR Rev 5’-AGGAGATGAGTACCAGCAGGTTG-3’ 
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2.2.13 Antibodies used for Western blot (WB) and immunofluorescence 
(IF) analysis 
 
Primary Antibodies 
Name Ordering no. Company Application Dilution Source 
AP4 040213 AbD Serotec WB; IF 1:1000;1:50 
1:50 
mouse 
E-cadherin 334000 Invitrogen WB 1:10 0 mouse 
α-tubulin T-9026 Sigma WB 1:1000 mouse 
SNAIL 3879S Cell Signaling IF 1:100 rabbit 
VSV V4888 Sigma WB 1:7500 rabbit 
p53 SC-126 Santa Cruz WB 1:1000 mouse 
ZEB1 SC-25388 Santa Cruz WB 1:1000 rabbit 
 
Secondary Antibodies 
Name/Conjugate Ordering no. Company Application Dilution Source 
anti-mouse/HRP # W4021 Promega WB 1:10,000 goat 
anti-rabbit/HRP # A0545 Sigma WB 1:10,000 goat 
anti-mouse/Alexa 
555 
# A21422 Invitrogen IF 1:500 goat 
anti-rabbit/Cy3 #715-165-150 Jackson Imm.  
Research 
IF 1:500 donkey 
     
 
2.3 Materials for animal experiments 
 
Name Source 
immunodeficient NOD/SCID mice Jackson Laboratory 
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2.4 Colon cancer samples 
 
The colon cancer RNA sample collection and its analysis for AP4 protein 
expression was described previously (Jackstadt et al., 2013). In brief, formalin 
fixed-, paraffin embedded (FFPE) colon cancer samples from 94 patients that 
underwent surgical tumor resection at the Ludwig-Maximilians-Universität 
München between 1994 and 2005 were obtained from the archives of the 
Institute of Pathology. All tumors were located on the right side of the colon. 
The study was performed according to the recommendations of the local ethics 
committee of the Medical Faculty of the Ludwig-Maximilians-Universität 
München (Shi et al., 2014; Siemens et al., 2013). 
 
2.5 Equipment 
 
Device Company 
5417C table-top centrifuge Eppendorf AG, Hamburg, Germany 
ABI 3130 genetic analyzer 
capillary sequencer 
Applied Biosystems, Foster City, USA 
Accu-Jet Pro Pipette BrandTech Scientific, Essex, CT,  
USA 
Axiovert 25 microscope 
 
 
Carl Zeiss GmbH, Oberkochen, 
Germany 
BD AccuriTM C6 
Flow Cytometer Instrument 
Accuri, Erembodegem, Belgium 
 
Biofuge fresco  Heraeus; Thermo Fisher Scientific, 
Inc., Waltham, MA, USA 
Biofuge pico table top centrifuge Heraeus; Thermo Fisher Scientific, 
Inc., Waltham, MA, USA 
CF40 Imager Kodak, Rochester, New York, USA 
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Fisherbrand FT-20E/365transilluminator Fisher Scientific GmbH, Schwerte, 
Germany 
Forma scientific CO2 water 
jacketed incubator 
Thermo Fisher Scientific, Inc., 
Waltham, MA, USA 
GeneAmp® PCR System 9700 Applied Biosystems, Foster City, USA 
Herasafe KS class II safety cabinet Thermo Fisher Scientific, Inc., 
Waltham, MA, USA 
HTU SONI130 Labortechnik G. Heinemann Ultraschall und 
Schwäbisch Gmünd, Germany 
ME2CNT membrane pump Vacuubrand GmbH & CO KG, 
Wertheim, Germany 
Megafuge 1.0R Heraeus; Thermo Fisher Scientific, 
Inc., Waltham, MA, USA 
Mini-PROTEAN®-electrophoresis 
system 
Bio-Rad, Munich, Germany 
MultiI age Light Cabinet Alpha Innotech, Johannesburg, 
South Africa 
Nalgene Cryo1°C Freezing Container Thermo Fisher Scientific Inc., 
Waltham, MA, USA 
ND 1000 NanoDrop Spectrophotometer NanoDrop products, Wilmington, DE, 
USA 
Neubauer counting chamber Carl Roth GmbH & Co, Karlsruhe, 
Germany 
Orion II illuminometer Berthold Technologies GmbH & Co. 
KG, Bad Wildbad, Germany 
PerfectBlue™ SEDEC 'Semi-Dry' 
blotting system 
Peqlab Biotechnologie GmbH, 
Erlangen, Germany 
Water bath Memmert GmbH, Schwabach, 
Germany 
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3 Methods 
3.1 Cell culture 
3.1.1 Starting cell culture from frozen cells 
 
Frozen cells were thawed in a 37°C water bath. Afterwards cells were 
transferred into a 15 ml falcon, centrifuged at 1200 rpm for 4 minutes. The cell 
pellet was washed the first time with HBSS-/- (Life Technologies), 
re-centrifuged, washed the second time with appropriate medium (see 2.2.3), 
then transferred into a flask. Cells were cultivated in an incubator at 37°C and 
5% CO2. 
 
3.1.2 Subculture of adherent cell lines 
 
Cell culture was watched using an inverted microscope to check confluence 
and confirm the absence of contaminants. The used medium was removed. 
The cell monolayer was washed with HBSS. 1×trypsin (1-2 ml per T75 flask) 
was added to the washed cell monolayer. The flask was kept in an incubator at 
37°C for 3-5 minutes or until cells were detached. After that, the flask was 
gently taped to release the adherent cells. Detachment was checked with a 
microscope. Cells were splitted and fresh serum-containing medium was 
added. Cells were cultivated in an incubator at 37°C and 5% of CO2. 
 
3.1.3 Cell counting 
 
Cells were detached from the surface of the dish by using trypsin and diluted 
with medium. A sterile pipet tip was used to transfer the cell suspension to the 
edge of Neubauer counting chamber (Roth). Cells were allowed to settle for a 
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few minutes before counting. The slide was viewed on a microscope with 
10×magnifications. A hand-held counter was used to count cells in each of four 
corner squares. The cell concentration can be determined with the following 
formula: cells/ml= total number of 4 corners×104/4. 
Coverslip and Neubauer counter chamber were rinsed with 70% ethanol. 
 
3.1.4 Cell storage 
 
Cells were trypsinized, centrifuged at 1200 rpm for 4 minutes and 
resuspended in storage medium. Aliquots in cryovials were stored in cell 
freezing container (Thermo Fisher Scientific) at -80°C for up to six months or in 
liquid nitrogen tank for long term storage.  
 
3.1.5 Transfection of oligonucleotides, vectors and constructs 
 
Most of the transfection experiments were performed in 6-well plates. 
1.0-4.0 × 105 cells per well were seeded in 2 ml medium. For each well, the 
transfection mixture contained 150 μl Opti-MEM (Life Technologies), 5 μl 
oligonucleotides (10 µM) or 4 μg DNA constructs and 10 μl HiPerFect (Qiagen) 
or 8μl FuGene reagent (Promega). The mixture was gently mixed by vortexing 
and incubated at room temperature for 10 minutes (for oligonucleotides) or 15 
minutes (for DNA constructs), then it was added dropwise to the cells, 
incubated for 24 - 48 hours until the cells were ready for the assay. 
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3.1.6 Generation of cell pools with conditional vectors 
 
  DLD-1 and SW480 colorectal cancer cells were transfected with pRTR or 
pRTS plasmids using FuGene reagents. After 24 hours, cells were transferred 
into media containing 4 μg/ml puromycin (Sigma; stock solution: 2 mg/ml in 
water) for one week or into media containing 800 μg/ml hygromycin (Invitrogen; 
stock solution 50 mg/ml) for two weeks. Homogeneity of the derived cell pools 
was tested by addition of 100 ng/ml DOX for 48 hours. After that GFP/RFP 
expression was evaluated by fluorescence microscopy and flow cytometry (Shi 
et al., 2014). 
 
3.2 Generation of the AP4 3’-UTR constructs 
3.2.1 Clone the AP4 3’-UTR constructs 
 
   
  The AP4 3’-UTR fragment containing the miR-15a/16-1 seed sequence was 
amplified by PCR using of the primers listed above (see 2.2.10) and inserted 
into the AgeI and EcoRV sites of the multiple cloning site of the pGL-3 vector. 
The reagents were: 2 μl 10×PCR buffer,1.2 μl dNTPs, 1.6 μl Fwd primer,1.6 μl 
Rev primer, 2 μl template (100 ng), 0.3 μl Hot Star, 1 μl DMSO and 10.3 μl 
ddH2O. The PCR program started at 94°C for 10 min for initial activation, 
3-step 35×cycling of 94°C for 1 min for denaturation, 56°C for 1 min for 
annealing and 72°C for 1 min for extension, then the final extension at 72°C for 
7 min. PCR results were detected by gel electrophoresis with a 1% agarose 
gel. 
  Mutations of the miR-15a/16-1 seed-matches were introduced using the 
QuickChange II Site-Directed Mutagenesis Kit (Stratagene) with 
oligonucleotides listed above (see 2.2.10) and confirmed by sequencing. 
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3.2.2 Colony PCR 
 
To identify the inserted positive transformants, a bacterial culture tube 
containing selective medium was prepared. In parall, 20 µl PCR reaction 
mixture containing dNTPs, PCR buffer, vector-specific primers, and FIREPol® 
DNA polymerase was prepared. A single colony was picked from the bacterial 
culture and transferred into the PCR reaction and thereafter inoculated in the 
culture tube overnight. 
PCR cycling conditions were as follows: 95°C for 5 minutes initial activation, 
followed by 25 cycles. Denaturation at 95°C for 30 seconds, annealing at 62°C 
for 30 seconds and 72°C for 1 minute or longer for extension, depending on 
the size of insert, and then 72°C for 2 minutes. PCR results were detected by 
gel electrophoresis with a 1% agarose gel. 
 
3.2.3 Ligation method 
 
The ligation mixture containing 3 μl PCR product (15 ng), 1 μl pGEM-T-Easy 
vector (5 ng), 1 μl 10×ligation buffer, 1 μl T4 DNA Ligase and 4 μl ddH2O, was 
gently mixed and placed overnight at 4°C. 
 
3.2.4 Transformation of heat shock-competent E. Coli XL1 blue 
 
Competent E. coli XL1 blue cells were thawed on ice for ~30 minutes and 
agar plates (containing the appropriate antibiotic) were kept at room 
temperature or in a 37°C incubator. The water bath was kept at 42°C. 100 ng 
plasmid was added to 25 μl of competent cells in a micro-centrifuge tube, 
gently mixed and incubated on ice for 30 minutes. Subsequently, each 
transformation tube was kept in the 42°C water bath for 90 seconds for heat 
shock and put back immediately on ice for 2 minutes. 500 μl LB medium 
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(without antibiotics) was added and the mixture was kept in the 37°C incubator 
for 60 minutes. Cells were centrifuged at 2000 rpm for 5 minutes, the major 
part of the supernatant was discarded. The remaining cells were plated on an 
agar plate containing antibiotics. A bent one-way inoculation needle was used 
to spread them as equally as possible. Finally, the plate was incubated 
upside-down at 37°C over night. 
 
3.2.5 Purification of plasmid DNA from E.coli 
 
For miniprep of plasmid DNA, bacteria were inoculated in a volume of 5 ml 
of LB-medium supplemented with ampicillin. DNA was either isolated using the 
QIAprep Spin Miniprep Kit (Qiagen) as follows: 
First, cells were centrifuged for 10 minutes at 4000 rpm. The pellet was 
resuspended in 250 µl of MP1 buffer, 250 µl of MP2 buffer and then incubated 
at room temperature for 5 minutes. The lysis buffer was neutralized by 250 µl 
of MP3 buffer and then centrifuged at 13000 rpm for 10 minutes. Subsequently, 
supernatant was transferred into a new tube, 700 µl of isopropanol was added 
and the mixtures were vortexed. Precipitated DNA was centrifuged at 
maximum speed for 15 minutes at room temperature, washed with 500 µl of 
70% ethanol and centrifuged again at maximum speed for 5 minutes. After 
discarding the ethanol, DNA was dried at room temperature and resuspended 
in 50 µl H2O. 
For midi-prep, the volume of LB-medium was 150 ml and the Pure Yield™ 
Plasmid Midiprep System (Promega) was utilized according to the 
manufacturer’s protocol.  
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3.2.6 Sequencing  
 
The following regents were mixed in a sterile tube: 1 μl Big Dye Terminator 
3V1.1 (Life Technologies), 2 μl 5×Sequencing buffer, 0.5 μl primer (10 μM), 1 
μl plasmid (1 μg/ml), 5.5 μl ddH2O. The compounds were gently mixed. The 
PCR program was 15 cycles of 96°C for 10 seconds and 60°C for 90 seconds. 
The DyeEx 2.0 Spin Kit (Qiagen) was used to remove dye terminators 
according to the manufacturer’s protocol. 4 μl purified DNA and 16 μl Hi-Di 
formamide were incubated at 90°C for 3 minutes and final sequencing was 
performed in an ABI3130 genetic analyzer capillary sequencer (Applied 
Biosystems). The 3130 Data Collection Software v3.0 was employed for 
performing sequencing. The sequencing analysis software 5.2 (Applied 
Biosystems) was utilized for analyzing the results. 
 
3.2.7 Enzyme Restriction 
 
3 μl of plasmid (~700 ng) were added to 2 μl enzyme buffer 1, 2 μl 10×BSA, 
2 μl AgeI, 2 μl EcoRV and ddH2O to add up to 20 μl. The reagents were gently 
mixed and placed at 37°C in a water bath for 3 hours. The results were 
detected on a 1% agarose gel, and purified with the QIAquick Gel Extraction 
Kit (Qiagen). 
 
3.3 Dual-reporter luciferase assays 
 
The term “dual-reporter” refers to the simultaneous expression and 
measurement of two individual reporter enzymes. Typically, the experimental 
reporter contains the 3’-UTR of interest, while the control reporter provides an 
internal control. After transfection, cells are assayed by measuring the 
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experimental reporter activity normalized to the internal control (Xu et al., 
2013). 
Firstly, 3 x 104 H1299 cells were seeded per well of a 12-well plate. After 24 
hours, cells were transfected with 100 ng empty pGL3 firefly reporter or the 
molar equivalent of a pGL3 construct. Additionally, 20 ng of Renilla reporter 
was co-transfected for normalization and either 25 nM of respective miRNA or 
nagative control oligonucleotide (Applied Biosystems) (Shi et al., 2014). 
After 48 hours incubation, a Dual-Luciferase reporter assay (Promega) was 
performed according to the manufacturer’s instructions. Luminescence 
intensities were measured with an Orion II illuminometer (Berthold) in 96-well 
format and analyzed with the SIMPLICITY software package (DLR) (Shi et al., 
2014). 
 
3.4 RNA isolation and Quantitative real-time PCR 
3.4.1 Isolation of RNA and reverse transcription reaction 
 
Total RNA extraction was performed using the High Pure RNA Isolation Kit 
(Roche) according to manufacturer’s manual. Concentration and quality were 
tested with a Nanodrop spectrophotometer. Furthermore, 1 μg of total RNA 
was used for the reverse transcription reaction to generate cDNA with the 
verso cDNA Kit (Thermo Fisher Scientific). 
For isolation of the small RNA fraction, especially microRNA enriched 
fraction, we employed the High Pure miRNA Isolation Kit (Roche) according to 
manufacturer’s instructions.  
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3.4.2 Quantitative real-time PCR (qPCR) 
 
In order to determine mRNA expression levels, the Fast SYBR Green 
Master Mix (Applied Biosystems) was applied for the real time PCR analysis. 
According to the standard protocol, 7.5 μl SYBR Green Master Mix, 5 μl H2O, 1 
μl cDNA and 1.5 μl Fwd-Rev mix primers (see 2.2.11) were added to each 
reaction. The program of the Light Cycler 480 System was as follows: 95°C for 
20 seconds, 40 cycles of 95°C for 1 second, 60°C for 20 seconds and 72°C 1 
for second, final 98°C for 10 seconds and 60°C for 1 minute. A house-keeping 
gene, namely β-actin, was required for the normalization of the results (Shi et 
al., 2014).  
To detect mature miR-15a/16-1 expression, the miRCURY LNA™ Universal 
RT microRNA PCR Kit (Exiqon), and miR-15a/16-1 specific primers (Exiqon) 
combined with SYBR® Green master mix (Exiqon) were used in the Light 
Cycler 480 System. The gene of SNORD48 served as the normalization of the 
results (Shi et al., 2014). 
 
3.5 Protein extraction and Western blot analysis 
3.5.1 Protein extraction 
 
Pre-incubated cells were treated in the presence/absence of the respective 
compounds and reached the ideal confluence. The plate was transferred 
immediately on ice and washed twice with precooled 1×PBS. Protein was 
harvested using a scraper and RIPA buffer, which contained protease and 
phosphatase inhibitors (Roche). The cell lysate was transferred to a new tube 
and sonified using a HTU SONI130 device with the intensity of 85% amplitude 
3 consecutive times and each time 5 seconds. Afterwards, the lysate was 
centrifuged at 13,000 rpm at 4°C for 20 minutes to separate supernatant and 
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debris. The protein lysate was transferred to a fresh tube for further protein 
concentration measurement or storage at -80°C immediately. 
The BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific) was utilized to 
measure protein concentration and the Skanlt RE Varioskan 2.4.3 algorithm 
(Thermo Fisher Scientific) was used to calculate the results. 
 
3.5.2 Western blot analysis 
 
Resolving gels were prepared with polyacrylamide concentrations of 10%, 
and covered with 4% stacking gels to analyze protein. 40-80 μg of protein was 
diluted with 2×Laemmli buffer with a final concentration of 5% 
β-mecaptoethanol (Sigma-Aldrich). The mixture was incubated at 95°C for 5 
minutes to denature protein, and loaded on the gels between two pre-stained 
protein ladders (Fermentas). Then, electrophoresis was performed at 90 V for 
the stacking gel and 120 V for the resolving gel in a 
Mini-PROTEAN®-electrophoresis system (Bio-Rad) with 1×Tris-glycine-SDS 
running buffer. 
In order to make the proteins accessible for antibody detection, proteins 
were transferred to an Immobilon-P polyvinylidene difluoride (PVDF) 
membrane (Millipore) using Towbin buffer. The PerfectBlueTM SEDES 
'Semi-Dry' blotting system (Peqlab) and the EPS 600 power supply 
(Pharmacia Biotech) at constant amperage of 100 mA per gel and a maximum 
voltage of 10 V for 30-90 minutes, depending on the size of the protein, were 
employed for Western blotting. 
To prevent of non-specific interaction, the membrane was placed in 5% skim 
milk in TBST for one hour at room temperature. Subsequently, the membrane 
was incubated with primary antibodies (see 2.2.13) overnight at 4°C. The 
membrane was washed twice in 1×TBST for 15 minutes each time, followed by 
one hour incubation with the horseradish-peroxidase (HRP)-conjugated 
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respective secondary antibody (see 2.2.13). After that, the membrane was 
rinsed twice in TBST for 15 minutes each time and 2 minutes in TBS. Western 
LightningTM Plus-ECL (Millipore Corporation) was used for abundantly 
expressed proteins (e.g. α-tubulin) and ImmobilonTM Western (Millipore 
Corporation) for proteins with weak expression. The signals were visualized 
using a CF40 Imager (Kodak). 
 
3.6 Boyden-chamber assay of migration and invasion 
 
For the last 48 hours cells were deprived of serum (0.1%). To analyze 
migration, 5 x 104 cells were seeded in the upper chamber of the 
Boyden-chamber in serum free medium. To analyze invasion, membranes 
were coated with Matrigel (BD Bioscience) at a final concentration of 3.3 ng/ml 
in serum free medium. Then 7 x 104 cells were seeded on the Matrigel in the 
upper chamber. As chemo-attractant, medium with 10% FBS was placed in the 
lower chamber. Migration or invasion toward 0.1% serum was used as a 
control. Cultures were maintained for 48 hours. Afterwards, non-motile cells at 
the top of the chamber were removed with q-tips and the cells in the bottom 
chamber were fixed with methanol and stained with DAPI. Five different fields 
per condition were evaluated using immunofluorescence microscopy. The 
average number of cells in the five fields per membrane was calculated. Each 
condition was performed in triplicate. The relative migration/invasion was 
calculated by the ratio of treated cells to control cells. The p-value was 
computed with a t-test (Shi et al., 2014). 
 
Methods 
42 
 
3.7 Immunofluorescence and confocal laser-scanning microscopy 
 
For immunofluorescence analysis, cultivated cells on glass cover-slides 
were fixed in 4% paraformaldehyde for 10 minutes under the chemical hood 
and washed three times with phosphate buffered saline (PBS). The cells were 
then permeabilized in 0.2% Triton X 100/PBS for 20 minutes and blocked with 
100% FBS for 1 hour. Primary and secondary antibodies are listed above (see 
2.2.13). DNA was stained with DAPI (Roth). Specimens were covered with 
ProLong Gold antifade (Invitrogen). LSM (laser scanning microscopy) images 
were captured with a confocal microscope (LSM 700; Zeiss) using a Plan 
Apochromat 20x/0.8 M27 objective, the ZEN 2009 software (Zeiss) and the 
following settings: image size 2048x2048 and 16 bit; pixel/dwell of 25.2 μs; 
pixel size 0.31 μm; laser power 2%; master gain 600-1000. After image 
capturing the original LSM files were converted into TIFF files. 
 
3.8 DNA content analysis by flow cytometry 
 
Cells were washed with PBS and fixed by addition of ice-cold 70% ethanol, 
then incubated over night at -20°C. Cells were stained with staining solution. 
After incubation for one hour at 37°C, cells were analyzed by flow cytometry 
using a CFlow6 device (Accuri). The p-value was computed with a t-test. 
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3.9 Analysis of colon cancer samples 
 
The colon cancer RNA sample collections and their analysis for AP4 protein 
expression were described previously (Jackstadt et al., 2013). miRNAs were 
isolated from 5 μm sections of FFPE tumor tissue samples after 
micro-dissection using the High Pure miRNA Isolation Kit (Roche) according to 
manufacturer’s instructions. cDNA was synthesized using 100 ng of isolated 
RNA enriched for small RNAs as a template. qRT microRNA PCR was 
performed in the Light Cycler 480 System using primers specific of 
hsa-miR-15a. Data was normalized to SNORD48 expression. All reactions 
were performed as technical duplicates. RT reactions and quantification were 
performed using the miRCURY LNA™ Universal RT microRNA PCR Kit  
(Exiqon) according to manufacturer’s instructions (Shi et al., 2014). 
 
3.10 Statistical analyses 
 
All data are presented as the mean value ± S.D. if not indicated otherwise. 
Differences between individual groups were analyzed by paired t tests. P 
values of p<0.05=*, p<0.02=**, p<0.001=*** were considered as statistically 
significant. To determine the correlation coefficient (r) and the significance (p) 
between the expression of AP4 protein and miR-15a the Pearson’s correlation 
algorithm was applied. Statistical analyses were performed using the SPSS 
software 19 package (SPSS Inc., Chicago, IL). The plots in Figure 20D and 
24A were generated with the GraphPad Prism software 6 (GraphPad Software 
Inc., La Jolla, CA). 
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4 Results 
4.1 p53 mediates down-regulation of AP4 after DNA damage 
 
  Previous results showed that AP4 is down-regulated after treatment with 
etoposide, which induces DNA damage (Jung et al., 2008). As DNA damage 
activates p53, we investigated whether AP4 repression is mediated by p53. 
We employed isogenic pairs of HCT116 and RKO CRC cell lines harboring 
either p53+/+ or p53-/- genotypes generated by homologous recombination 
(Bunz et al., 1998; Sur et al., 2009). After induction of DNA damage by 
treatment with doxorubicin (DOXO), AP4 levels were decreased only in 
p53-proficient cell lines (Figure 5A and 5B). When the same cell lines were 
treated with Nutlin-3a, a specific inhibitor of the p53-E3-ligase MDM2 (mouse 
double minute 2 homolog), similar results were obtained (Figure 5C).  
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Figure 5 p53-dependent down-regulation of AP4 after DNA damage in HCT116 
and RKO colorectal cancer cells 
(A-C) Detection of the indicated proteins by Western blot analysis. α-tubulin served as 
a loading control. (A) HCT116 and (B) RKO cells with the indicated genotypes were 
treated with Doxorubicin (0.5 μg/ml) for the indicated periods. (C) HCT116 and RKO 
cells with the indicated genotypes were treated with Nutlin-3a (10 μM) for the 
indicated periods. 
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  Furthermore, SW480/pRTR-p53-VSV pools were generated and treated 
with doxycycline (DOX). When p53 expression was induced, down-regulation 
of AP4 expression on the protein and mRNA levels was detected (Figure 6A 
and 6B).  
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Figure 6 Down-regulation of AP4 by ectopic expression of p53 
(A) Western blot analysis of the indicated proteins in SW480/pRTR-p53-VSV pools 
after treatment with DOX (100ng/ml) for the indicated periods. α-tubulin served as a 
loading control. (B) qPCR analysis of AP4 mRNA expression in 
SW480/pRTR-p53-VSV pools after treatment of DOX for the indicated periods. B: 
results represent the mean value +/- S.D. (n=3).  
 
  Taken together, activation of p53 is necessary and mediates the 
down-regulation of AP4 in colon cancer cell lines.  
 
4.2 AP4 is a direct target of miR-15a and miR-16-1 
 
  Our previous genome-wide ChIP-Seq analysis in the SW480 cell line 
ectopically expressing p53 did not show p53 occupancy within a distance of 30 
kbp up- or down-stream of the AP4 promoter (Hermeking et al., in preparation). 
Based on these results, AP4 is presumably not a direct transcriptional target of 
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p53 indicating that there is probably another mediator involved in this 
regulation. Recently, several studies demonstrateded that miRNAs target the 
3’-UTR of transcriptional factors and that these miRNAs also are induced by 
p53 (Kim et al., 2011b; Sachdeva et al., 2009; Siemens et al., 2011). Therefore, 
a reasonable explanation for the indirect down-regulation of AP4 by p53 could 
be that miRNAs participate in this pathway. Therefore, we conducted an in 
silico analysis with the AP4 3’-UTR using four different algorithms to identify 
putative miRNAs seed-matching sequences (Figure 7A). In each of the four 
algorithms, miR-15a, miR-101 and miR-144 were predicted to target the AP4 
3’-UTR, whereas three algorithms identified potential target sites of miR-16-1 
(Figure 7A). Interestingly, miR-15a and miR-16-1 are encoded by the same 
intron of the DLEU2 precursor-RNA and belong to the same microRNA family. 
Both of them are induced by ectopic p53 (Fabbri et al., 2011; Suzuki et al., 
2009). Since miR-101 and miR-144 are presumably not regulated by p53, we 
focused on miR-15a and miR-16-1 as putative mediators of AP4 
down-regulation. Furthermore, the seed-matching sequences of miR-15a and 
miR-16-1 in the 3’-UTR of AP4 are conserved among species, which may 
imply the functional importance of this sequence motif (Figure 7B).  
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Figure 7 Bioinformatics identification of AP4 as a target of miR-15a/16-1  
(A) Bioinformatics prediction of seed-matching sequences in the AP4 3’-UTR using 
four different algorithms. (B) Location and possible base-pairing within a predicted 
miR-15a/16-1 seed-matching sequences in the AP4 3’-UTR. Conservation of 
sequences is shown as red shading. Vertical lines represent probable base pairings. 
 
  After transfection of pre-miR-15a, pre-miR-16-1 or a combination of both 
pre-miRNAs into the colon cancer cell line SW480, AP4 was repressed 
dramatically (Figure 8A). Similar results were obtained after transfection of 
miR-15a/16-1 using the vector TW-miR-15a/16-1 in SW480 cells (Figure 8B). 
After transfection of AP4-specific siRNA, down-regulation of AP4 was detected 
in SW480 cells (Figure 8C). Transfection of pre-miR-15a, pre-miR-16-1 or a 
combination of both lead to a down-regulation of AP4 on the mRNA level 
(Figure 8D). Notably, the combination resulted in a more pronounced 
repression of AP4 than the single the pre-miRNAs, which suggests that 
miR-15a and miR-16-1 may cooperate on the two overlapping seed-matching 
sequences in the AP4 3’-UTR. 
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Figure 8 Repression of AP4 by miR-15a/16-1 in SW480 cells 
(A) Western blot analysis of AP4 protein expression in SW480 cells after the 
transfection of the indicated pre-miR oligonucleotides (total 25 nM) for 48 hours. 
α-tubulin served as a loading control. (B) The indicated TW vector (4 μg/well) was 
transiently transfected into SW480 cells. The indicated proteins were detected. 
α-tubulin served as a loading control. (C) AP4-specific siRNAs transfected into 
SW480 cells resulted in decreased AP4 expression. (D) qPCR analysis of AP4 mRNA 
after the transfection of pre-miR-15a and/or pre-miR-16-1 mimics (total 25 nM), for the 
indicated periods. D: results represent the mean value +/- S.D. (n=3). Rene Jackstadt 
performed the analyses and generated Figure 8 A and D. 
 
   H1299 cells were transfected with pre-miR-15a and pre-miR-16-1 
oligonucleotides simultaneously with pGL3-AP4 3’-UTR and a construct 
encoding Renilla-luciferase. The two miRNAs lead to a similar and significant 
reduction of luciferase activity in dual-luciferase reporter system (Figure 9A). 
Furthermore, a reporter with mutated sequences in the seed-matching sites 
was resistant to down-regulation by pre-miR-15a and pre-miR-16-1 (Fig. 9B).  
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Figure 9 Regulation of AP4 by miR-15a/16-1 via a conserved seed-matching site 
(A) In vitro mutagenesis of the miR-15a/16-1 seed-matching in the AP4 3’-UTR. Red 
shading indicates the conserved seed-sequences and blue letters indicate the 
mutations that had been included into the respective reporter constructs used in (B). 
(B) Dual-luciferase reporter analysis of the AP4 3’-UTR in H1299 cells 48 hours after 
transfection of pre-miR-15a or pre-miR-16-1. B: results represent the mean value +/- 
S.D. (n=3). 
 
  Collectively, the results indicate that miR-15a and miR-16-1 directly target 
the AP4 3’-UTR and repress AP4 expression by binding to these 
seed-matching sequences. 
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4.3 p53 decreases AP4 by p53 via miR-15a/16-1 
 
  In Figure 5A we showed that AP4 was repressed by p53 after DNA damage. 
Furthermore, DNA damage also resulted in a significant p53-dependent 
increase in mature miR-15a level (Figure 10A). After ectopic expression of p53 
in SW480 cells, the induction of pri-miR-15a/16-1 and repression of AP4 
mRNA were also observed (Figure 10B and 6B). 
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Figure 10 Up-regulation of miR-15a/16-1 by p53 in colon cancer cell lines 
(A) HCT116 cells with the indicated genotype were treated with DOXO (0.5 μg/ml) for 
24 hours. Then mature miRNAs were analyzed by qPCR. (B) qPCR analysis of 
pri-miR-15a/16-1 expression after activation of p53 by addition of DOX for the 
indicated periods in SW480/pRTR-p53-VSV cells. A and B: results represent the 
mean value +/- S.D. (n=3). 
 
  In order to determine whether miR-15a/16-1 is required for the repression of 
AP4 by p53, we employed a miR-15a/16-1-specific sponge, which was 
previously described in (Bonci et al., 2008). Indeed, transfection of a plasmid 
encoding the miR-15a/16-1-specific sponge prevented the repression of AP4 
after treatment with Nutlin-3a in HCT116 cells (Figure 11A). In p53-deficient 
HCT116 cells, AP4 expression was not affected by this reagent. Furthermore, 
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the induction of pri-miR-15a/16-1 and repression of AP4 mRNA could be 
prevented by transfection of the miR-15a/16-1-specific sponge into SW480 
cells expressing a conditional p53 allele (Figure 11B). Interestingly, treatment 
with the miR-15a/16-1-specific sponge could reverse the p53-induced down- 
or up-regulation of several genes involved in EMT and MET as Snail, VIM and 
CDH1 on the mRNA level (Figure 11B). Furthermore, when the induction of 
miR-15a/16-1 was prevented by transfection of the miR-15a/16-1-specific 
sponge, the repression of migration by ectopic 53 was alleviated in 
SW480/pRTR-p53-VSV cells (Figure 11C).  
Figure 11 p53 represses AP4 and EMT- related markers via miR-15a/16-1 
(A) HCT116 cells with the indicated genotype were transfected with plasmids 
encoding the miR-15a/16-1-specific sponge for 24 hours and subsequently treated 
with Nutlin-3a for 48 hours. The indicated proteins were detected by Western blot 
analysis. α-tubulin served as a loading control. (B) SW480/pRTR-p53-VSV cells were 
                 A 
- - + + - - + +
- + + - - + + - Nutlin-3a
- p53
- AP4
- α-tubulin
p53 +/+ p53 -/-
HCT116
miR-15a/16-1 sponge
 
B                  C 
0
0.5
1
1.5
2
2.5
3
3.5
-DOX
+DOX
+sponge
+sponge +DOX
SW480/pRTR-p53-VSV
fo
ld
c
h
a
n
g
e
[m
R
N
A
]
**
*
**
*
**
*
** *
*
** **
**
**
**
**
** **
*
**
- DOX
DOX
miR-15a/16-1 sponge
miR-15a/16-1 sponge + DOX
 
 
ctrl. sponge
miR-15a/16-1 sponge
DOX-
-
+
+
-
+
+
+
-
re
la
ti
v
e
m
ig
ra
ti
o
n
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
*
*
 
Results 
52 
 
transfected with the miR-15a/16-1-specifc sponge for 24 hours and subsequently 
DOX was added for 48 hours. The indicated mRNAs were detected by qPCR. (C) 
Determination of migration in a transwell Boyden-chamber assay in 
SW480/pRTR-p53-VSV cells. First, cells were transfected with the 
miR-15a/16-1-specific sponge or control sponge for 24 hours and subsequently DOX 
was added for 48 hours. For the last 48 hours, the serum concentration was reduced 
to 0.1%. In the end, cells were fixed and stained with DAPI. The average numbers of 
cells in five fields per membrane were recorded in three different inserts. Relative 
migration is given in the value of test cells to control cells. B and C: results represent 
the mean value +/- S.D. (n=3). 
 
  In summary, these data reveal that the repression of AP4 by p53 is mediated 
by miR-15a/16-1 and that p53 inhibits EMT in SW480 cells via inducing 
miR-15a/16-1. 
 
4.4 miR-15a/16-1 induces MET by repressing AP4 
 
  Recently, our group revealed that AP4 induces EMT, promotes 
migration/invasion and contributes to metastasis by directly regulating SNAIL 
and E-cadherin expression (Jackstadt et al., 2013). This data suggest that 
ectopic expression of miR-15a and miR-16-1 could induce MET and repress 
metastasis by repressing AP4 expression. Indeed, transfection of pre-miR-15a 
and pre-miR-16-1 in the mesenchymal cell line SW480 negatively regulated 
EMT-related markers and further induced MET. The mesenchymal markers 
SNAIL and VIM were significantly repressed while the epithelial marker CDH1 
was up-regulated on the mRNA level (Figure 12). 
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Figure 12 Regulation of EMT-related markers by transfection of pre-miR-15a 
and pre-miR-16-1 in SW480 cells 
Expression of the indicated mRNAs (A) SNAIL (B) VIM (C) CDH1 (D) ZEB1 was 
determined by qPCR analysis after transfection of the indicated pre-miRNAs (total 25 
nM) for the indicated periods. Results represent the mean value +/- S.D. (n=3). Rene 
Jackstadt performed the analyses and generated the figures. 
 
  Similar results were obtained using the pri-miR-15a/16-1 conditional 
overexpression system in SW480 cells (Figure 13A, 13B and 13C). The 
epithelial marker E-cadherin was up-regulated on both protein and mRNA 
levels after ectopic miR-15a/16-1 expression (Figure 13A and 13B), whereas 
the mesenchymal markers SNAIL and VIM were repressed on the mRNA level 
(Figure 13C). An immunofluorescence analysis confirmed the down-regulation 
of AP4 and SNAIL after ectopic expression of miR-15a/16-1 (Figure 13D). 
 
 
 
 
 
 
 
 
A                B             C            D   
Results 
54 
 
A B C 
 
SW480/
pRTS-miR-15a/16-1
- ZEB1
- AP4
- β-actin
0 48 hrs + DOX
- E-cadherin
 
miR-15a
0
5
10
15
20
25
30
35
40 -DOX +DOX
fo
ld
c
h
a
n
g
e
[m
R
N
A
]
***
**
**
miR-16-1 CDH1
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
AP4 SNAIL VIM
-DOX +DOX
fo
ld
c
h
a
n
g
e
[m
R
N
A
]
*
 
D 
  
DNA AP4
DOX:
+
-
DNA SNAIL
SW480/pRTS-miR-15a/16-1
 
 
Figure 13 Regulation of EMT-related markers by ectopic expression of 
miR-15a/16-1 
(A) Western blot and (B and C) qPCR analysis of the indicated protein, miRNAs and 
mRNAs after 48 hours addition of DOX in SW480/pRTS-miR-15a/16-1 cells. (D) 72 
hours after the addition of DOX, SW480/pRTS-miR-15a/16-1 cells were stained and 
subjected to confocal microscopy. Nuclear DNA was detected by DAPI staining. Scale 
bars represent 50 μm. B and C: results represent the mean value +/- S.D. (n=3).  
 
  In addition, overexpression of miR-15a/16-1 inhibited wound closure in 
SW480/pRTS-miR-15a/16-1 cells (Figure 14A and 14B). A significant 
repression of migration and invasion was also detected in a Boyden-chamber 
assay (Figure 14C). 
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Figure 14 Ectopic miR-15a/16-1 inhibits would closure, invasion and migration 
(A) Representative pictures and (B) quantification of a wound healing assay after 72 
hours activation of miR-15a/16-1 in SW480/pRTS-miR-15a/16-1 cells. Wound closure 
was determined 48 hours after scratching. Mitomycin C was applied for 2 hours 
before scratching. (C) Determination of invasion and migration of 
SW480/pRTS-miR-15a/16-1 cells as described in Figure 11C. To analyze invasion, 
membranes were coated with Matrigel (3.3 ng/ml in the respective medium). A, B and 
C: results represent the mean value +/- S.D. (n=3). 
 
  Then, the TargetScan algorithm was used to analyse the 3’-UTRs of other 
known EMT-related factors, e.g. SNAIL1, SNAIL2, CDH1, ZEB1, ZEB2 and 
TWIST1. As shown in Figure 15, a putative miR-15a/16-1 seed-matching site 
could not be detected in the 3’-UTR of other EMT-inducing TFs. Therefore, 
AP4 presumably represent the only known EMT-TF, which is directly targeted 
by miR-15a/16-1. 
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Figure 15 Bioinformatics prediction of seed-matching sequences in the 3’-UTR 
of other EMT-inducing transcription factors 
In silico analysis of the 3′-UTR of EMT- inducing transcription factors. The 3′-UTRs of 
(A) SNAI1, (B) SNAI2, (C) CDH1, (D) ZEB1, (E) ZEB2, and (F) TWIST1 were 
analyzed for the presence of miRNAs seed-matching sequences by using the 
algorithm of TargetScan. (G) Color keys indicated the degree of seed/seed-matching 
sequence conservation. 
 
  In support of this notion, the repression of migration by overexpression of 
miR-15a was alleviated after ectopic expression of AP4 in a conditional 
expression system, which lacks its original 3’-UTR (Figure 16).  
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Figure 16 Inhibition of migration by miR-15a/16-1 is attenuated by ectopic AP4 
expression 
After 72 hours treatment with DOX or vehicle, SW480/pRTR-AP4-VSV cells were 
transfected with the indicated oligonucleotides; 24 hours before seeding the cells on 
the Boyden-chamber membrane, serum was reduced to 0.1% as described in Figure 
11C. Results represent the mean value +/- S.D. (n=3). 
 
  Collectively, these results demonstrate that miR-15a/16-1 inhibits EMT by 
repressing AP4 in SW480 cells.  
 
4.5 Role of AP4 in cell cycle inhibition by miR-15a/16-1 
   
  Recently, several reports showed that miR-15a/16-1 induces apoptosis and 
inhibits cell cycle progression by targeting BCL2 and CCND1, respectively 
(Bonci et al., 2008; Chen et al., 2008; Cimmino et al., 2005). In contrast to that, 
AP4 promotes cell proliferation, at least in part, by repressing the 
cyclin-dependent kinase (CDK) inhibitor p21 (Jung et al., 2008). Here, we 
hypothesized that the miR-15a/16-1/AP4 axis inhibits cell cycle progression in 
colorectal cancer cells. After transfection of pre-miR-15a, it caused a 
pronounced and significant G1 arrest in SW480 CRC cells (Figure 17A and 
17B). When a conditional AP4 allele lacking its 3’-UTR, therefore being 
resistant to miR-15a/16-1, was activated simultaneously with the transfection 
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of miR-15a, a G1 arrest was prevented and cells continued to cycle, as 
indicated by an unchanged amount of cells in the G1 and S phase.  
Consequently, down-regulation of AP4 by miR-15a/16-1 is not only 
necessary for mediating EMT, but also plays a key role in the inhibition of the 
cell cycle progression by miR-15a/16-1 in colon cancer cells.  
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Figure 17 G1 arrest by miR-15a/16-1 is rescued by ectopic AP4 expression 
(A and B) Cell cycle distribution as determined by DNA content analysis using flow 
cytometry. SW480/pRTR-AP4-VSV cells were treated with DOX or vehicle for 72 
hours, and the last 24 hours transfected with the indicated oligonucleotides, then cells 
were fixed and DNA was stained with propidium iodide. Results represent the mean 
value +/- S.D. (n=3). 
 
4.6 miR-15a/16-1 represses metastasis of CRC Xenografts 
 
Tsai et al demonstrated that activation of EMT promotes local tumor invasion, 
intravasation and extravasation of systemic circulation (Tsai et al., 2012). 
Therefore, we further investigated the role of miR-15a/16-1 in the lung 
metastases formation using engrafted SW620 cells in mice. Hence, we stably 
introduced a luciferase 2 (luc2) and miR-15a/16-1 expression cassette using 
     -DOX          +DOX 
    pre-miR-15a     DOX + pre-miR-15a 
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lentiviral transduction in SW620 colorectal cancer cells. Furthermore, 
overexpression of miR-15a/16-1 decreased AP4 expression on the protein and 
mRNA levels (Figure 18A and 18B). Moreover, mesenchymal markers like 
SNAIL and VIM were down-regulated (Figure 18B). Additionally, migration and 
invasion were repressed by ectopic miR-15a/16-1 expression as determined in 
a transwell Boyden-chamber assay (Figure 18C). 
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Figure 18 Stable expression of miR-15a/16-1 inhibits AP4 expression, 
mesenchymal markers, migration and invasion  
 (A) Western blot analysis of AP4 protein expression and (B) qPCR analysis of the 
indicated RNAs in SW620-Luc2 cells stably expressing miR-15a/16-1 or the 
respective control vector. α -tubulin served as a loading control. (C) Transwell 
Boyden-chamber assay of cellular migration and invasion of SW620-Luc2 cells. After 
72 hours, cells were seeded into a transwell chamber and analyzed as described in 
Figure 11C. B and C (left panel): results represent the mean +/- S.D. (n=3). C (right 
panel): results represent the mean value +/- S.D. (n=2). Rene Jackstadt performed 
the analyses and generated the Figures 18A and B. 
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However, overexpression of miR-15a/16-1 did not cause a reduced 
proliferation in SW620 cells (Figure 19). This may be due to the lower levels of 
miR-15a/16-1 driven by the lentiviral vector compared to those resulting from 
transient transfection of pre-miR-15a in the experiments shown in Figure 17. 
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Figure 19 Analysis of cell proliferation in SW620-Luc2 cells harboring a 
miR-15a/16-1 vector or empty vector 
Stable expression of miR-15a/16-1 did not lead to a decreased proliferation in 
SW620-Luc2 cells. Rene Jackstadt performed the analyses and generated the figure. 
 
The cells harboring the miR-15a/16-1 stable expression or a control vector 
were injected in the tail vein of immune-compromised non-obese 
diabetic/severe combined immune-deficient (NOD/SCID) mice. Then, the 
spreading and colonization of cells was monitored over time in a non-invasive 
manner using luminescence imaging. Within four weeks, lung metastases 
were detected. In particular, weaker luminescence signals were detected in 
mice injected with miR-15a/16-1 expressing cells compared to control cells 
after nine weeks (Figure 20A and 20B). The number of lung metastases in the 
control group was higher than in the group treated with miR-15a/16-1 
expressing cells (Figure 20C, left panel). Hematoxylin and eosin (H&E) 
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staining showed ectopic expression of miR-15a/16-1 repressed colonization of 
SW620 cells in the lung (Figure 20C, right panel). Furthermore, the total 
number of metastatic nodules declined as a result of ectopic expression of 
miR-15a/16-1 detected by histological quantification of the lung (Figure 20D). 
In summary, these results show that miR-15a/16-1 represses metastatic 
colonization and growth of CRC tumor cells in vivo. 
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Figure 20. miR-15a/16-1 suppresses lung metastases formation in vivo 
(A) SW620-Luc2 cells were introduced into NOD/SCID mice (n=7 for each group) by 
tail vein injection. Bioluminescence signals were recorded at the indicated time-points. 
Bioluminescence signals collected per mouse were depicted as “total flux”. (B) 
Representative bioluminescence images were recorded at the indicated time-points 
after injection. (C, left panel) Lungs were resected 9 weeks after injection. Arrows 
indicate metastatic tumor nodules. (C, right panel) Representative examples of the 
H&E staining of the resected lungs are shown. Scale bars represent 100 μm. (D) 
Quantification of metastatic tumor nodules in lung per mouse. Results represent the 
mean value +/- S.D. (n=7). Rene Jackstadt performed the analyses and generated the 
Figure 20A-D. 
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4.7 AP4 directly represses miR-15a/16-1 
 
miRNAs often form feedback loops with transcriptional factors (Ebert and 
Sharp, 2012). Therefore, we hypothesized that AP4 may directly repress 
miR-15a/16-1 expression. In fact, the expression of primary and mature 
miR-15a/16-1 was decreased significantly after ectopic AP4 expression in 
SW480/pRTR-AP4-VSV cells (Figure 21A and 21B). On the other hand, 
down-regulation of AP4 by two AP4-specific miRNAs caused an up-regulation 
of the pri-miR-15a/16-1 transcript in SW480 (Figure 21C). 
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Figure 21. Activated AP4 represses miR-15a/16-1 expression in SW480 cell line 
qPCR analysis of miR-15a/16-1 expression in SW480/pRTR-AP4-VSV cells after 
addition of DOX for the indicated periods (A) or 48 hours (B). (C) pri-miR-15a/16-1 
expression was detected in SW480 cells harboring episomal plasmids for conditional 
expression of two different miRNAs directed against AP4 (AP4mi1 or AP4mi2) or a 
non-silencing miRNA (NonS). Cells were treated with DOX for 48 hours. A, B and C: 
results represent the mean value +/- S.D. (n=3). Rene Jackstadt performed the 
analyses and generated Figure 21C. 
 
Furthermore, ChIP followed by the next generation sequencing (ChIP-Seq) 
was employed in DLD-1/pRTR-AP4-VSV pools ectopically expressing AP4. 
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The data revealed that AP4 occupies regions in the vicinity of the two 
alternative DLEU2 transcription start sites (Figure 22), the host gene of 
miR-15a/16-1. 
 
 
 
Figure 22. AP4 occupies the two DLEU2 transcription start sites 
(Upper panel) Representation of ChIP-Seq results obtained after ectopic expression 
of AP4 for 24 hours in DLD-1 cells. Results were visualized by using the UCSC 
genome browser. (Lower panel) Schematic map of the human DLEU2 locus. AP4 
binding motifs are indicated by vertical arrows above the gene. Dashed lines indicate 
the amplicons used for qChIP analysis. Exons are indicated by rectangles and 
miRNAs by hairpins. Rene Jackstadt performed the analyses and generated the 
figure. 
 
These results were further confirmed by qChIP in DLD-1 cells with activated 
AP4 expression (Figure 23A). Additionally, occupancy by endogenous AP4 
was detected at DLEU2 promoters in SW620 cells (Figure 23B).  
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Figure 23 Regulation of miR-15a/16-1 by AP4 
(A) DLD-1/pRTR-AP4-VSV cells were treated with DOX for 24 hours and subjected to 
qChIP analysis with an AP4-specific or, as a reference, IgG antibody. AchR 
amplification served as a control. (B) SW620 cells were subjected to qChIP analysis 
with an AP4-specific or, as a reference, IgG antibody. AchR amplification served as a 
control. A and B: results represent the mean value +/- S.D. (n=3). Rene Jackstadt 
performed the analyses and generated Figure 23 A and B. 
 
Taken together, AP4 and miR-15a/16-1 generate a double-negative 
feedback loop and they can regulate each other. 
 
4.8 Inverse correlation between AP4 and miR-15a/16-1 expression 
in primary CRC 
 
  As described above, we demonstrated that AP4 and miR-15a/16-1 form a 
double-negative feedback loop in colon cancer cell lines. Next, we determined 
whether they display a negative correlation in human patient samples. 
Therefore, we extracted small RNA fractions and detected the miR-15a 
expression from 94 colon cancer samples of a case-control cohort of matched 
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patients with and without distant liver metastasis. AP4 protein expression was 
detected as described in (Jackstadt et al., 2013). All data supported a 
significant negative correlation between AP4 and miR-15a. In fact, increased 
expression of AP4 inversely correlated with decreased miR-15a expression 
(Figure 24A). Particularly, only two of the ten cases with the most remarkable 
miR-15a expression showed an AP4 expression higher than the median, 
whereas eight samples with the lowest miR-15a expression presented AP4 
expression above the overall average (Table II). In addition, five of the samples 
with lowest miR-15a expression were from patients that developed liver 
metastases within five years after resection of the primary tumor, while only 
two of those with the highest miR-15a expression showed distant metastases. 
Using the Oncomine database, we could observe a significant inverse 
correlation between DLEU2 and AP4 (Figure 24B) in the Notterman et al 
dataset (Notterman et al., 2001). AP4 expression was up-regulated in the 
cancer samples compared to normal cases, whereas DLEU2 was repressed. 
 
Table II Sub-analysis using cases with the most prominent miR-15a expression 
levels 
 
The top ten cases of high and low miR-15a expression were analyzed regarding their 
expression of AP4 and the presence/absence of liver metastases. AP4‚ high and low 
categorizations were based on the overall-median. p-values were calculated applying 
the Student’s t-test. Helge Siemens performed the analyses and generated the Table 
II. 
 
 
Results 
67 
 
A B 
r = -0.417
p < 0.001
n=8
n=25
n=41 n=20
0 1 2 3
 
colorectal
adenocarcinoma
(n=18)
colorectal
normal tissue
(n=18)
DLEU2
AP4
Notterman et al.
P = 0.025
P = 0.001
 
 
Figure 24 Inverse correlations of AP4 and miR-15a/16-1 expression in colon 
cancer samples 
(A) 94 samples of right sided colon cancer were subjected to Exiqon qPCR analysis of 
miR-15a expression. AP4 protein expression was previously determined by using 
immunohistochemistry and was linked to miR-15a expression. The AP4 expression 
levels were assigned to four groups representing none (0), weak (1), moderate (2) 
and strong (3) expression. Significance and correlation coefficient were calculated 
with the Pearson correlation algorithm. (B) Analysis of mRNA expression levels of the 
indicated genes as deposited in the Oncomine database. Light blue indicates samples 
from normal colorectal tissue. Dark blue indicates samples from colorectal 
adenocarcinomas. P-values were provided by the Oncomine database. Helge 
Siemens performed the analyses and generated Figure A. 
 
Collectively, an inverse correlation of miR-15a/16-1 and AP4 expression is 
also detectable in human colon cancer samples.  
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5 Discussion 
5.1  p53-regulated miRNAs target transcription factors to regulate 
EMT 
 
  In 2007, the miR-34 family was identified as the first miRNA directly 
regulated by p53 and shown to induce apoptosis and senescence (Chang et 
al., 2007; Corney et al., 2007; Raver-Shapira et al., 2007). Furthermore, 
ectopic p53 was shown to up-regulate miRNAs which regulate cell cycle, tumor 
metastasis and stemness by targeting transcription factors (Chang et al., 2011; 
Chen et al., 2013a; Sachdeva et al., 2009; Shimono et al., 2009; Xu et al., 
2009). 
EMT is a key process at early stages of metastasis (Thiery, 2002b). Besides 
the results described here, a number of other studies showed that p53 
regulates EMT/MET through miRNA-mediated inhibition of transcription factors 
(Gregory et al., 2008; Hahn et al., 2013; Kim et al., 2011a; Kim et al., 2011b; 
Siemens et al., 2011). For example, p53-induced miR-34a represses EMT by 
decreasing SNAIL expression. Interestingly, ectopic SNAIL also 
down-regulates miR-34a in colorectal cancer cell lines (Siemens et al., 2011). 
These findings illustrate that miR-34a and SNAIL form a double-negative 
feedback loop, which is controlled by p53. In addition, Kim et al. showed that 
up-regulated miR-34 reduces Axin2 expression, which further increases 
GSK-3β nuclear location and leads to decreased SNAIL expression in colon 
cancer cells (Kim et al., 2013; Kim et al., 2011a). Furthermore, miR-34 can 
also regulate EMT through targeting another transcription factor, ZNF281, 
which is induced by SNAIL (Hahn et al., 2013). Moreover, ectopic miR-34a 
decreases the expression of the stem cell markers CD44 and Bmi1 (Siemens 
et al., 2011) indicating that stem cell-like features are also regulated by the 
p53/miR-34a axis.  
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  It is known that c-MYC promotes EMT in cancer (Raver-Shapira et al., 2007; 
Sakuma et al., 2012; Smith et al., 2009), and studies reported that p53 could 
repress EMT through inducing the two tumor suppressor miRNAs miR-34 and 
miR-145 which both repress c-MYC (Christoffersen et al., 2010; Sachdeva et 
al., 2009). 
Apart from the miR-34 family, Kim et al found that the miR-200 family, 
including miR-200a/b/c, miR-141 and miR-429, is induced by p53 (Kim et al., 
2011b). The miR-200/ZEB1/2 axis is also involved in the negative regulation of 
EMT by p53 (Chang et al., 2011). 
  Previous results imply AP4 as a new mediator of EMT. Ectopic expression of 
AP4 directly represses E-Cadherin and induces SNAIL, VIM, N-cadherin and 
FOS in colon cancer cell lines (Jackstadt et al., 2013). AP4 is repressed by p53 
in CRC cell lines, while miR-15a/16-1 levels are elevated. Here, we 
demonstrated that p53 decreases AP4 expression and inhibits EMT through 
inducing miR-15a/16-1. The details of the miR-15a/16-1/AP4 double-negative 
feedback loop are discussed below (see 5.2 and 5.3). 
  Previous studies showed that SNAIL is induced by AP4 and SNAIL 
represses miR-34a (Jackstadt et al., 2013; Siemens et al., 2011). Hence, 
miR-15a/16-1 may positively correlate with miR-34 by repressing AP4, which 
would presumably result in a decrease in SNAIL expression and de-repression 
of miR-34a. Indeed, Bandi et al reported that miR-15a/16-1 and miR-34 can 
co-operate in non-small cell lung cancer (Bandi and Vassella, 2011). Similarly, 
both miR-15a/16-1 and miR-200 regulate migration and invasion by targeting 
vascular endothelial growth factor (VEGF) (Roybal et al., 2011; Sun et al., 
2013; Wang et al., 2012). Therefore, miR-15a/16-1 and miR-200 may 
co-regulate EMT through VEGF.  
Taken together, our results indicate that the miR-15a/16-1/AP4 axis 
represents another p53/miRNAs/EMT-TF circuitry involved in the regulation of 
the EMT process. Moreover, miR-15a/16-1 may cooperate with miR-34 and 
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miR-200 to prevent erroneous loss of cellular differentiation due to aberrant 
signal, which may emanate from the cellular environment (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 The regulation of EMT/MET by p53 
The blue background indicates the miR-15a/16-1/AP4 circuitry involved in the 
regulation of EMT/MET and metastasis, which was identified in this thesis study. In 
addition, two more loops between EMT-TFs and p53-induced microRNAs are known, 
namely the miR-34a/SNAIL and miR-200/ZEB1/2 loops. 
 
5.2 Repression of miR-15/16-1 by AP4 
 
We employed an AP4 conditional expression system in the colon cancer cell 
line SW480 to show that AP4 can repress miR-15a/16-1 at both primary and 
mature miRNA levels. Next, we utilized ChIP and confirmed that there are two 
alternatives AP4 bound regions in the vicinity of DLEU2 transcription start sites, 
the host gene of miR-15a/16-1. The results reveal that AP4 represses DLEU2 
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directly. Hence, miR-15a/16-1 and AP4 generate a double-negative feedback 
loop, similar to the previously reported miR-34/SNAIL1 and miR-200/ZEB1 
feedback loops (Figure 25). The parallel presence of the three different loops 
may convey robustness to the system. 
 
5.3 The role of the miR-15a/16-1/AP4 axis in EMT 
 
As AP4 was described as a new EMT mediator in colon cancer (Jackstadt et 
al., 2013), we continued to focus on whether miR-15a/16-1 could regulate the 
EMT process by inhibiting AP4 expression. It is known that activated p53 
represses EMT through the miR-34/SNAIL1 and miR-200/ZEB1/2 cascades. 
Here, we identified the miR-15a/16-1/AP4 double-negative feedback loop as 
an additional module regulated by p53. In addition, we also confirmed that 
ectopic expression of miR-15a/16-1 can induce MET in colorectal cancer cell 
lines. Similar results indicate that miR-16-1 may also regulate EMT in other 
types of cancer. Li et al reported that activated miR-16-1 represses migration 
and invasion in glioma cells (Li et al., 2013). Furthermore, ectopic miR-16-1 
represses cell proliferation dramatically in U251 cells, but has no significant 
impact on cell apoptosis. However, the functional role of miR-15/16-1 in cell 
migration and invasion in this study is not fully understood.  
Recently, Guo et al demonstrated that miR-15a inhibits EMT through the 
down-regulation of Bmi-1 (Guo et al., 2014). Bmi-1 expression decreases 
E-cadherin expression. However, the authors did not detect different 
expression of miR-16-1 in pancreatic cancer samples compared to normal 
pancreatic tissues.  
Previous results showed miR-15a/16-1 is frequently deleted and regulates 
cell apoptosis and proliferation in cancer (Bandi et al., 2009; Calin et al., 2004; 
Chen et al., 2008; Lerner et al., 2009). However, how miR-15a/16-1 functions 
as a tumor suppressor is not fully understood. Here we show that miR-15a and 
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miR-16-1 reverses EMT in colon cancer and promotes MET. These findings 
suggest that down-regulation and/or inactivation of miR-15a/16-1 may 
contribute to tumor progression by promoting metastatic traits in addition to 
conteracting apoptosis and promoting cell proliferation. 
  
5.4 The role of miR-15a/16-1/AP4 axis in cell cycle regulation 
 
The mammalian cell division cycle, referred to as the cell cycle, is a strictly 
regulated process and a highly conserved pathway modulated by 
cyclin-dependent kinases (CDK). Several studies demonstrated that p21, 
which is induced by p53, connects p53 tightly to the cell cycle as it is a CDK 
inhibitor (Abbas and Dutta, 2009). Having established that activated AP4 
represses p21 expression in the cell lines MCF-7 and U2OS (Jung et al., 2008), 
we assumed that miR-15a/16-1 could influence cell cycle progression by 
repressing AP4. Indeed, a G1 arrest was observed after transfection of 
pre-miR-15a in SW480 cells. Concomitant expression of a conditional AP4 
allele lacking miR-15a seed-matching sequences attenuated the G1 arrest 
mediated by miR-15a. This indicates that the cell cycle inhibitory function of 
miR-15a/16-1 requires repression of AP4. 
miR-15a/16-1 was previously reported to induce a G1 cell cycle arrest by 
repressing Cyclin D1 (CCND1). Interestingly, a truncation of CCND1 mRNA 
which removes the seed-matching sites in the 3’-UTR, prevents repression by 
miR-15a in mantle cell lymphoma (Chen et al., 2008). Liu et al. implied that 
miR-15a/16-1 also represses cycle-dependent kinase (CDK) CDK6, CyclinD3 
(CCND3) and Cyclin E1 (CCNE1) to inhibit G1/S transition (Liu et al., 2008). 
Bandi et al showed that the regulation of cell cycle by miR-15a/16-1 in 
non-small cell lung cancer is dependent on the Retinoblastoma (Rb) protein 
(Bandi et al., 2009). E2F1 is a downstream target of Rb, and repressed by Rb. 
Ectopic E2F1 can induce G1/S transition and unexpectedly promote 
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miR-15a/16-1 expression (Ofir et al., 2011). Therefore, miR-15a/16-1 may 
attenuate the influence of E2F1 in cell proliferation.  
 
 
 
 
 
 
 
 
 
 
Figure26 The miR-15a/16-1/AP4 axis in the cell cycle regulation 
miR-15a/16-1 regulates cell cycle through AP4 and other factors. Black arrows 
indicate previously described regulations, while purple arrows present the results from 
this study. 
 
  AP4 promotes cell cycle progression by repression of p21 (Jung et al., 2008). 
Furthermore, AP4 promotes cell cycle progression by repression of 
miR-15/16-1, which itself has a cell cycle inhibitory effect, in part by repressing 
AP4. Therefore, the tightly controlled balance between AP4 and miR-15a/16-1 
levels may represent a critical component in the regulation of cell cycle 
progression, which is frequently disrupted during tumorigenesis (Figure 26). 
 
5.5 The role of miR-15a/16-1/AP4 axis in experimental tumors 
 
  As described above, EMT is required for the initial step in metastasis 
formation and is necessary for extravasion. Therefore, we analyzed the impact 
of miR-15a/16-1 on the formation of lung metastasis by xenografted CRC cells 
in mice. Mice injected with SW620 cells expressing miR-15a/16-1 showed a 
 E2F1 
CCND1/CCND3/CCNE1/CDK6 miR-15a/16-1 Rb 
 AP4 p53 p21 
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lower colonization in the lung and inhibits tumor formation in vivo. 
  Bonci et al reported that a knock-down of miR-15a/16-1 promotes prostate 
cell proliferation and tumorigenesis in immunodeficient NOD/SCID mice. 
Ectopic miR-15a/16-1 limits tumor growth in xenografts. WNT3A, which is 
correlated with tumor invasion, is repressed by miR-15a/16-1 (Bonci et al., 
2008). Furthermore, monoclonal B cell lymphocytosis (MBL), CLL and 
Non-Hodgkin Lymphoma develop in miR-15a/16-1 knock-out mice. Of note, 
cell cycle mediators, like CCND2, CCND3, CDK4/6, are up-regulated in this 
system (Klein et al., 2010).   
  Collectively, these studies establish that miR-15a/16-1 has a tumor 
suppressor role in vivo. In addition, miR-15a and miR-16-1 regulate both cell 
cycle progression and EMT-related processes in vivo.  
 
5.6 The correlation of miR-15a/16-1 and AP4 in clinical samples 
 
  Our results showed that miR-15a/16-1 and AP4 generate a double-negative 
feedback loop in vitro. Furthermore, we detected that miR-15a and AP4 
display a negative correlation in human patient samples. In the dataset from 
Notterman et al, AP4 expression negatively correlates with expression of the 
miR-15a/16-1 host gene DLEU2 (Notterman et al., 2001). According to these 
results, AP4 is increased in the samples of colorectal adenocarcinomas, while 
the DLEU2 gene is down-regulated in the same stage of cancer. The reduced 
expression of miR-15a/16-1 in colon cancer may further cause the 
up-regulation of AP4, which can enhance EMT and promote metastasis. 
Recently, Guo et al demonstrated that miR-15a expression negatively 
correlates with Bmi-1 expression in 42 pancreatic cancer samples (Guo et al., 
2014). Furthermore, a decreased expression of Bmi-1 was associated with 
longer patient survival. In pancreatic cancer, higher expression of miR-15a was 
detected in pre-malignant tissues when compared to tumor tissues. Therefore, 
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the miR-15a/16-1 and AP4 loop may also be active in other types of cancer 
besides colorectal cancer.   
Several studies showed that miR-15a/16-1 is frequently deleted and/or 
down-regulated in chronic lymphocytic leukemia. miR-15a/16-1 is located on 
chromosome 13q14.3. This 30-kb region is deleted or down-regulated in ~68% 
(41 in 60) of B cell chronic lymphocytic leukemia (B-CLL) (Calin et al., 2002). 
Liu et al demonstrated that the 13q14.3 deletion which contains the 10-kb 
MDR often occurs in CLL. The MDR harbors the promoter of miR-15a/16-1 
host gene DLEU2 (Figure4) (Liu et al., 1997). 
 
5.7 miR-15a/16-1, AP4 and future perspective 
 
Bmi-1 is one of the key regulators of stem cell maintenance and 
miR-15a/16-1 represses Bmi-1 expression in ovarian cancer (Bhattacharya et 
al., 2009). This implies that miR-15a/16-1 could also act as a regulator of 
stemness. Activated AP4 induces stem the cell markers CD44 and LGR5 in 
colon cancer cell lines. Therefore, miR-15a/16-1 may inhibit stemness by 
repressing AP4 and Bmi-1 in colon cancer cell lines. 
miR-15a/16-1 is down-regulated in many kinds of cancers, like CLL, prostate, 
colon, and lung cancer (Bandi et al., 2009; Klein et al., 2010; Notterman et al., 
2001). In contrast, AP4 promotes cell proliferation, induces EMT and 
metastasis in vivo. Therefore, a replacement therapy approach restoring 
expression of miR-15a/16-1 in humans could regulate multiple oncogenic 
signaling pathways. For example it could inhibit EMT through AP4, cell cycle 
progression via CCND1, stemness by targeting Bmi-1, and decrease VEGF 
signaling and affect angiogenesis. Collectively, these results suggest that 
restoring miR-15a/16-1 expression could be a promising therapeutic strategy. 
Interestingly, a trial with a similar replacement therapy approach is underway 
for miR-34 (Bader, 2012).
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6 Summary 
Previous results demonstrated that 13q14, the genomic location of DLEU2, 
which encodes the miR-15a/16-1 microRNAs, is deleted in more than 50% of 
chronic lymphatic leukemia (CLL) cases. miR-15a/16-1 down-regulates BCL2 
and induces cell apoptosis. miR-15a/16-1 also inhibits cell cycle regulators,  
such as CCND1/3, CCNE2 and CDK2, thereby inducing a G1 arrest. These 
data indicate that miR-15a and miR-16-1 may represent tumor suppressors. 
The Hermeking lab had recently described AP4 as a new inducer of EMT and 
tumor metastasis. Furthermore, AP4 was found to be repressed after DNA 
damage. In this thesis it was shown that this repression occurs in a 
p53-dependent manner. Since miR-15a/16-1 is induced by p53 and predicted 
to target the AP4 3’-UTR, we investigated whether and how miR-15a/16-1 
could also exert its tumor suppressive function by repression of AP4. We 
determined that p53-induced miR-15a/16-1 directly represses AP4.  
Furthermore, miR-15/16-1 induces MET and promotes the epithelial state in 
the colorectal cancer cell line SW480. In addition, AP4 bound to the two 
alternative transcription start sites of DLEU2 and represses miR-15a/16-1 
expression. Therefore, miR-15a/16-1 and AP4 form a double-negative 
feedback loop similar to the previously reported miR-34/SNAIL and 
miR-200/ZEB1/2 loops, which are also regulated by p53. 
In human colorectal cancer samples, miR-15a/16-1 showed a negative 
correlation with AP4 expression. In addition, xenograft experiments showed 
that stable expression of miR-15a/16-1 diminishes lung metastasis formation 
of colorectal cancer cells in vivo.  
In conclusion, the findings of this study significantly enhance our 
understanding of the function of miR-15a/16-1 as a tumor suppressor in colon 
cancer. Additionally, the results indicate that replacement of miR-15a/16-1 
could be a promising therapeutic strategy warranting further research. 
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7 Zusammenfassung 
 
Vorherige Ergebnisse zeigten, dass die chromosomal Region 13q14, in der 
das dLEU2 Gen liegt, welches die MikroRNAs miR-15a/16-1 kodiert, in mehr 
als 50% aller chronisch-lymphatischen Leukämien (CLL) deletiert vorliegt. 
miR-15a/16-1 induziert Apoptose indem es Bcl2 hemmt. Zudem hemmt 
miR-15a/16-1 die Zellzyklusregulatoren CCND1/3, CCNE2 und CDK2, 
wodurch es einen G1-Arrest induziert. Diese Daten zeigen, dass miR-15a und 
miR-16 Tumorsuppressoren darstellen. Das Hermeking Labor hat AP4 vor 
kurzem als neuen Induktor von EMT und Tumormetastasierung beschrieben. 
Zudem fanden sie, dass AP4 nach DNA-Schädigung herunterreguliert wird. In 
dieser Arbeit konnte gezeigt werden, dass dies in einer p53-abhängigen Weise 
geschieht. Da miR-15a/16-1 durch p53 induziert wird und der 3'-UTR von AP4 
ein Ziel von miR-15a/16-1 ist, wurde untersucht, ob und wie miR-15a/16-1 
seine Tumor-unterdrückende Funktion durch Repression durch AP4 vermittelt. 
Es konnte gezeigt werden, dass miR-15a/16-1 direkt AP4 unterdrückt. 
Außerdem, induziert ektopisches miR-15a/16-1 MET in der 
Darmkrebs-Zelllinie SW480. Desweiteren bindet AP4 an die zwei alternativen 
Transkriptionsstartstellen des dLEU2 Gens und unterdrückt so die Expression 
von miR-15a/16-1. Somit bilden miR-15a/16-1 und AP4 eine negative 
Rückkopplungsschleife ähnlich den miR-34/SNAIL und miR-200/ZEB1/2 
Schleifen, die auch durch p53 reguliert werden. In menschlichen 
Darmkrebspräparaten zeigte miR-15a/16-1 eine negative Korrelation mit AP4 
Expression. Darüber hinaus resultierte die stabile Expression miR-15a/16-1 in 
kolorektalen Krebszellen in einer verminderten Bildung von 
Lungenmetastasen in xenotransplantierten Mäusen. 
Die Ergebnisse dieser Studie tragen wesentlich zu unserem Verständnis der 
Funktion des Tumor-Suppressors miR-15a/16-1 bei Darmkrebs bei. Zusätzlich 
zeigen die Ergebnisse, dass die Rekonstitution von miR-15a/16-1 in Tumoren 
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ein vielversprechender therapeutischer Ansatz sein könnte, der weitere 
Forschung in dieser Richtung rechtfertigt.  
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8 Publications 
 
The results of this thesis have been recently published: 
 
Lei Shi*, Rene Jackstadt*, Helge Siemens, Huihui Li, Thomas Kirchner, Heiko 
Hermeking. p53-induced miR-15a/16-1 and AP4 form a double-negative 
feedback loop to regulate epithelial-mesenchymal transition and metastasis in 
colorectal cancer. Cancer Research. 2014 Jan 15; 74(2): 532-42.  
 
(*: equally contributing first authors; Impact Factor 2013: 8.65) 
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